Publications

Publications 2024

  1. Andresen K, Klæboe LG, Lie ØH, Broch K, Kvaslerud AB, Bosse G, Hopp E, de Lange C, Haugaa KH, Edvardsen T (2024)
    No adverse association between exercise exposure and diffuse myocardial fibrosis in male endurance athletes
    Sci Rep, 14 (1), 6581
    DOI 10.1038/s41598-024-57233-5, PubMed 38503845
  2. De Bortoli A, Nordøy I, Connelly JP, Viermyr HK, Bjerkreim RH, Broch K, Olsen PAS, Gude E, Fevang B, Jørgensen SF, Trøseid M, Steen T, Aukrust P, Andreassen AK, Skarpengland T (2024)
    Diagnostics, treatment and outcomes of cardiac sarcoidosis in a Norwegian cohort
    Int J Cardiol, 400, 131809
    DOI 10.1016/j.ijcard.2024.131809, PubMed 38272129
  3. Raju SC, Molinaro A, Awoyemi A, Jørgensen SF, Braadland PR, Nendl A, Seljeflot I, Ueland PM, McCann A, Aukrust P, Vestad B, Mayerhofer C, Broch K, Gullestad L, Lappegård KT, Halvorsen B, Kristiansen K, Hov JR, Trøseid M (2024)
    Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity
    Genome Med, 16 (1), 27
    DOI 10.1186/s13073-024-01296-6, PubMed 38331891
  4. Ribic D, Remme EW, Smiseth OA, Massey RJ, Eek CH, Kvitting JP, Gullestad L, Broch K, Russell K (2024)
    Non-invasive myocardial work in aortic stenosis: validation and improvement in left ventricular pressure estimation
    Eur Heart J Cardiovasc Imaging, 25 (2), 201-212
    DOI 10.1093/ehjci/jead227, PubMed 37672652

Publications 2023

  1. Arora S, Zimmermann FM, Solberg OG, Nytrøen K, Aaberge L, Okada K, Ahn JM, Honda Y, Khush KK, Angeras O, Karason K, Gullestad L, Fearon WF (2023)
    Prognostic value of intravascular ultrasound early after heart transplantation
    Eur Heart J, 44 (48), 5160-5162
    DOI 10.1093/eurheartj/ehad648, PubMed 37850514
  2. Berg ES, Tegn NK, Abdelnoor M, Røysland K, Ryalen PC, Aaberge L, Eek C, Øie E, Juliebø V, Gjertsen E, Ranhoff AH, Gullestad L, Nordstrand N, Bendz B, After Eighty Study Investigators (2023)
    Long-Term Outcomes of Invasive vs Conservative Strategies for Older Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
    J Am Coll Cardiol, 82 (21), 2021-2030
    DOI 10.1016/j.jacc.2023.09.809, PubMed 37968019
  3. Berg R, Clemmensen TS, Petersen MS, Mogensen LJH, Christiansen M, Rolid K, Nytrøen K, Møller BK, Gullestad L, Eiskjær H, Koefoed-Nielsen P (2023)
    Kinetics of Torque Teno virus in heart transplant patients
    Hum Immunol, 84 (12), 110720
    DOI 10.1016/j.humimm.2023.110720, PubMed 37867096
  4. Birkeland KI, Meling S, Alsnes IV, Svensson E, Gullestad L, Jenssen TG (2023)
    New international recommendations for type 2 diabetes - consequences for treatment practice in Norway?
    Tidsskr Nor Laegeforen, 143 (3)
    DOI 10.4045/tidsskr.22.0672, PubMed 36811420
  5. Christensen AH, Wyller VBB, Nygaard S, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Saul JP, Døhlen G (2023)
    Factors Associated With Sinoatrial Reinnervation After Heart Transplantation
    Transplant Direct, 9 (12), e1553
    DOI 10.1097/TXD.0000000000001553, PubMed 37928482
  6. Dodgson CS, Beitnes JO, Kløve SF, Herstad J, Opdahl A, Undseth R, Eek CH, Broch K, Gullestad L, Aaberge L, Lunde K, Bendz B, Lie ØH (2023)
    An investigator-sponsored pragmatic randomized controlled trial of AntiCoagulation vs AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation: Rationale and design of ACASA-TAVI
    Am Heart J, 265, 225-232
    DOI 10.1016/j.ahj.2023.08.010, PubMed 37634655
  7. Holt MF, Flø A, Bjørnø V, Husebye T, Knudsen EC, Hodt A, Gustavsen A, Kristiansen HA, Raki M, Broch K, Wien TN, Gude E (2023)
    A man in his seventies with fatigue and renal failure
    Tidsskr Nor Laegeforen, 143 (9)
    DOI 10.4045/tidsskr.22.0679, PubMed 37341412
  8. Holt MF, Flø A, Ravnestad H, Bjørnø V, Gullestad L, Andreassen AK, Broch K, Gude E (2023)
    Invasive haemodynamics at rest and exercise in cardiac amyloidosis
    ESC Heart Fail, 11 (2), 1263-1268
    DOI 10.1002/ehf2.14621, PubMed 38158705
  9. Krämer BK, Hauske SJ, Chilton R, Mann JFE, Gullestad L, Fitchett D, Mattheus M, Steubl D, Wanner C (2023)
    Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
    J Diabetes Complications, 37 (9), 108588
    DOI 10.1016/j.jdiacomp.2023.108588, PubMed 37633072
  10. Nendl A, Raju SC, Broch K, Mayerhofer CCK, Holm K, Halvorsen B, Lappegård KT, Moscavitch S, Hov JR, Seljeflot I, Trøseid M, Awoyemi A (2023)
    Intestinal fatty acid binding protein is associated with cardiac function and gut dysbiosis in chronic heart failure
    Front Cardiovasc Med, 10, 1160030
    DOI 10.3389/fcvm.2023.1160030, PubMed 37332580
  11. Prapiadou S, Živković L, Thorand B, George MJ, van der Laan SW, Malik R, Herder C, Koenig W, Ueland T, Kleveland O, Aukrust P, Gullestad L, Bernhagen J, Pasterkamp G, Peters A, Hingorani AD, Rosand J, Dichgans M, Anderson CD, Georgakis MK (2023)
    Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis
    medRxiv
    DOI 10.1101/2023.03.24.23287543, PubMed 37034659
  12. Prapiadou S, Živković L, Thorand B, George MJ, van der Laan SW, Malik R, Herder C, Koenig W, Ueland T, Kleveland O, Aukrust P, Gullestad L, Bernhagen J, Pasterkamp G, Peters A, Hingorani AD, Rosand J, Dichgans M, Anderson CD, Georgakis MK (2023)
    Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis
    Circulation, 149 (9), 669-683
    DOI 10.1161/CIRCULATIONAHA.123.064974, PubMed 38152968
  13. Rafique M, Solberg OG, Gullestad L, Bendz B, Murbræch K, Nytrøen K, Rolid K, Lunde K (2023)
    Effects of high-intensity interval training on cardiac remodelling, function and coronary microcirculation in de novo heart transplant patients: a substudy of the HITTS randomised controlled trial
    BMJ Open Sport Exerc Med, 9 (3), e001331
    DOI 10.1136/bmjsem-2022-001331, PubMed 37440977
  14. Ravnestad H, Andersen R, Birkeland S, Svalebjørg M, Lingaas PS, Gude E, Gullestad L, Kvitting JP, Broch K, Andreassen AK (2023)
    Pulmonary endarterectomy and balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: Comparison of changes in hemodynamics and functional capacity
    Pulm Circ, 13 (1), e12199
    DOI 10.1002/pul2.12199, PubMed 36788941
  15. Sasi A, Romaine A, Erusappan PM, Melleby AO, Hasic A, Dahl CP, Broch K, Almaas VM, Puertas RD, Roderick HL, Lunde IG, Sjaastad I, Vistnes M, Christensen G (2023)
    Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development
    Matrix Biol Plus, 19-20, 100135
    DOI 10.1016/j.mbplus.2023.100135, PubMed 38076279
  16. Solberg OG, Aaberge L, Bosse G, Ueland T, Gullestad L, Aukrust P, Stavem K (2023)
    Microvascular function and inflammatory activation in Takotsubo cardiomyopathy
    ESC Heart Fail, 10 (5), 3216-3222
    DOI 10.1002/ehf2.14461, PubMed 37537779
  17. Sverre E, Munkhaugen J, Kristiansen O, Weedon-Fekjaer H, Peersen K, Gjertsen E, Gullestad L, Bergan S, Husebye E, Vethe NT (2023)
    Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease
    Pharmacol Res Perspect, 11 (3), e01089
    DOI 10.1002/prp2.1089, PubMed 37186070
  18. Woxholt S, Ueland T, Aukrust P, Anstensrud AK, Broch K, Tøllefsen IM, Ryan L, Bendz B, Hopp E, Kløw NE, Seljeflot I, Halvorsen B, Dahl TB, Huse C, Andersen GØ, Gullestad L, Wiseth R, Amundsen BH, Damas JK, Kleveland O (2023)
    Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
    Open Heart, 10 (2)
    DOI 10.1136/openhrt-2023-002301, PubMed 37591633

Publications 2022

  1. Bardan S, Kvaslerud AB, Andresen K, Kløve SF, Edvardsen T, Gullestad L, Broch K (2022)
    Intravenous ferric derisomaltose in iron-deficient patients undergoing transcatheter aortic valve implantation due to severe aortic stenosis: study protocol of the randomised controlled IIISAS trial
    BMJ Open, 12 (9), e059546
    DOI 10.1136/bmjopen-2021-059546, PubMed 36691165
  2. Baysa A, Maghazachi AA, Sand KL, Campesan M, Zaglia T, Mongillo M, Giorgio M, Di Lisa F, Gullestad L, Mariero LH, Vaage J, Valen G, Stensløkken KO (2022)
    Toll-like receptor 9 signaling after myocardial infarction: Role of p66ShcA adaptor protein
    Biochem Biophys Res Commun, 644, 70-78
    DOI 10.1016/j.bbrc.2022.12.085, PubMed 36634584
  3. Brautaset Englund KV, Østby CM, Broch K, Ueland T, Aukrust P, Gude E, Andreassen AK, Gullestad L (2022)
    Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo
    Clin Transplant, 36 (7), e14695
    DOI 10.1111/ctr.14695, PubMed 35532871
  4. Fontaine MAC, Jin H, Gagliardi M, Rousch M, Wijnands E, Stoll M, Li X, Schurgers L, Reutelingsperger C, Schalkwijk C, van den Akker NMS, Molin DGM, Gullestad L, Eritsland J, Hoffman P, Skjelland M, Andersen GØ, Aukrust P, Karel J, Smirnov E, Halvorsen B, Temmerman L, Biessen EAL (2022)
    Blood Milieu in Acute Myocardial Infarction Reprograms Human Macrophages for Trauma Repair
    Adv Sci (Weinh), 10 (5), e2203053
    DOI 10.1002/advs.202203053, PubMed 36526599
  5. Hunt TE, Traaen GM, Aakerøy L, Bendz C, Øverland B, Akre H, Steinshamn S, Loennechen JP, Hegbom F, Broch K, Lie ØH, Lyseggen E, Haugaa KH, Gullestad L, Anfinsen OG (2022)
    Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: A randomized controlled trial
    Heart Rhythm, 19 (9), 1433-1441
    DOI 10.1016/j.hrthm.2022.06.016, PubMed 35716856
  6. Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, Woxholt S, Yang K, Sharma K, Tøllefsen IM, Bendz B, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Quiles-Jiménez A, Bjerkeli V, Bendz C, Kleveland O, Stensaeth KH, Opdahl A, Kløw NE, Andersen GØ, Wiseth R, Halvorsen B, Gullestad L et al. (2022)
    Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial
    EBioMedicine, 80, 104013
    DOI 10.1016/j.ebiom.2022.104013, PubMed 35504178
  7. Kvaslerud AB, Bardan S, Andresen K, Kløve SF, Fagerland MW, Edvardsen T, Gullestad L, Broch K (2022)
    Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial
    Eur J Heart Fail, 24 (7), 1269-1279
    DOI 10.1002/ejhf.2557, PubMed 35579454
  8. Kvaslerud AB, Gude E, Eriksen G, Andreassen AK, Gullestad L, Broch K (2022)
    Diastolic Dysfunction Is Unmasked on Exercise in Patients With Asymptomatic, Severe Aortic Stenosis: An Invasive Hemodynamic Study
    Circ Heart Fail, 15 (2), e009253
    DOI 10.1161/CIRCHEARTFAILURE.121.009253, PubMed 35137599
  9. Nygaard S, Christensen AH, Sletner L, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Døhlen G, Saul JP, Wyller VBB (2022)
    Predictors of Hypertension Development 1 Year After Heart Transplantation
    Transplantation, 106 (8), 1656-1665
    DOI 10.1097/TP.0000000000004068, PubMed 35238853
  10. Skjølsvik ET, Haugen Lie Ø, Chivulescu M, Ribe M, Castrini AI, Broch K, Pripp AH, Edvardsen T, Haugaa KH (2022)
    Progression of cardiac disease in patients with lamin A/C mutations
    Eur Heart J Cardiovasc Imaging, 23 (4), 543-550
    DOI 10.1093/ehjci/jeab057, PubMed 33824984
  11. Traaen GM, Akre H, Loennechen JP, Gullestad L (2022)
    Reply to Lalonde et al.: Why Would Physiologic Support with Continuous Positive Airway Pressure Not Improve Outcomes in Patients with Atrial Fibrillation with Sleep Apnea?
    Am J Respir Crit Care Med, 205 (9), 1129-1130
    DOI 10.1164/rccm.202112-2738LE, PubMed 35226823
  12. Vergaro G, Gentile F, Aimo A, Januzzi JL, Richards AM, Lam CSP, de Boer RA, Meems LMG, Latini R, Staszewsky L, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K et al. (2022)
    Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure
    ESC Heart Fail, 9 (4), 2084-2095
    DOI 10.1002/ehf2.13883, PubMed 35510529

Publications 2021

  1. Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Krzysztof Wranicz J, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C et al. (2021)
    Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
    Eur Heart J, 42 (6), 700-710
    DOI 10.1093/eurheartj/ehaa943, PubMed 33351892
  2. Ahn JM, Zimmermann FM, Arora S, Solberg OG, Angerås O, Rolid K, Rafique M, Aaberge L, Karason K, Okada K, Luikart H, Khush KK, Honda Y, Pijls NHJ, Lee SE, Kim JJ, Park SJ, Gullestad L, Fearon WF (2021)
    Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation
    Eur Heart J, 42 (48), 4918-4929
    DOI 10.1093/eurheartj/ehab568, PubMed 34665224
  3. Ahn JM, Zimmermann FM, Gullestad L, Angerås O, Karason K, Russell K, Lunde K, Okada K, Luikart H, Khush KK, Honda Y, Pijls NHJ, Lee SE, Kim JJ, Park SJ, Solberg OG, Fearon WF (2021)
    Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart Transplantation
    J Am Coll Cardiol, 78 (24), 2425-2435
    DOI 10.1016/j.jacc.2021.10.009, PubMed 34886963
  4. Aukrust P, Kleveland O, Gullestad L (2021)
    Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction
    JACC Basic Transl Sci, 6 (5), 444-446
    DOI 10.1016/j.jacbts.2021.01.007, PubMed 34102669
  5. Awoyemi A, Mayerhofer C, Felix AS, Hov JR, Moscavitch SD, Lappegård KT, Hovland A, Halvorsen S, Halvorsen B, Gregersen I, Svardal A, Berge RK, Hansen SH, Götz A, Holm K, Aukrust P, Åkra S, Seljeflot I, Solheim S, Lorenzo A, Gullestad L, Trøseid M, Broch K (2021)
    Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial
    EBioMedicine, 70, 103511
    DOI 10.1016/j.ebiom.2021.103511, PubMed 34329947
  6. Brautaset Englund KV, Østby CM, Rolid K, Gude E, Andreassen AK, Gullestad L, Broch K (2021)
    Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial
    J Heart Lung Transplant, 40 (5), 359-367
    DOI 10.1016/j.healun.2021.01.1390, PubMed 33612360
  7. Brautaset Englund KV, Østby CM, Tjønnås G, Gude E, Andreassen AK, Gullestad L, Broch K (2021)
    Prevalence of iron deficiency in heart transplant recipients
    Clin Transplant, 35 (8), e14346
    DOI 10.1111/ctr.14346, PubMed 33969559
  8. Broch K, Anstensrud AK, Woxholt S, Andersen GØ, Gullestad L (2021)
    Reply: Clarification Regarding the Lack of Heart Failure Events in the ASSAIL-MI Trial
    J Am Coll Cardiol, 78 (6), 637-638
    DOI 10.1016/j.jacc.2021.06.005, PubMed 34353542
  9. Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Bendz C, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L (2021)
    Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
    J Am Coll Cardiol, 77 (15), 1845-1855
    DOI 10.1016/j.jacc.2021.02.049, PubMed 33858620
  10. Broch K, Brautaset Englund KV, Gullestad L (2021)
    Reply: Safety of intravenous iron in heart transplant patients: Comment to paper by Brautaset Englund et al
    J Heart Lung Transplant, 40 (10), 1247-1248
    DOI 10.1016/j.healun.2021.07.007, PubMed 34384682
  11. Bürker BS, Malt UF, Gude E, Grov I, Relbo Authen A, Dew MA, Gullestad L (2021)
    Symptoms of anxiety after heart transplantation and their association with mortality: A secondary analysis
    Clin Transplant, 35 (7), e14323
    DOI 10.1111/ctr.14323, PubMed 33882158
  12. Christensen AH, Nygaard S, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Døhlen G, Saul JP, Wyller VBB (2021)
    Early Signs of Sinoatrial Reinnervation in the Transplanted Heart
    Transplantation, 105 (9), 2086-2096
    DOI 10.1097/TP.0000000000003580, PubMed 33323767
  13. Christensen AH, Nygaard S, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Døhlen G, Saul JP, Wyller VBB (2021)
    Strong evidence for parasympathetic sinoatrial reinnervation after heart transplantation
    J Heart Lung Transplant, 41 (7), 898-909
    DOI 10.1016/j.healun.2021.11.005, PubMed 34924265
  14. Frisk M, Le C, Shen X, Røe ÅT, Hou Y, Manfra O, Silva GJJ, van Hout I, Norden ES, Aronsen JM, Laasmaa M, Espe EKS, Zouein FA, Lambert RR, Dahl CP, Sjaastad I, Lunde IG, Coffey S, Cataliotti A, Gullestad L, Tønnessen T, Jones PP, Altara R, Louch WE (2021)
    Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction
    J Am Coll Cardiol, 77 (4), 405-419
    DOI 10.1016/j.jacc.2020.11.044, PubMed 33509397
  15. Helseth R, Kleveland O, Ueland T, Wiseth R, Damas JK, Broch K, Michelsen A, Bendz B, Gullestad L, Aukrust P, Seljeflot I (2021)
    Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
    Open Heart, 8 (1)
    DOI 10.1136/openhrt-2020-001492, PubMed 33972404
  16. Holt MF, Michelsen AE, Shahini N, Bjørkelund E, Bendz CH, Massey RJ, Schjalm C, Halvorsen B, Broch K, Ueland T, Gullestad L, Nilsson PH, Aukrust P, Mollnes TE, Louwe MC (2021)
    The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure
    Front Immunol, 12, 800978
    DOI 10.3389/fimmu.2021.800978, PubMed 35003128
  17. Kotchetkov R, Susman D, Bhutani D, Broch K, Dispenzieri A, Buadi FK (2021)
    Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein
    Int J Cancer, 148 (11), 2807-2814
    DOI 10.1002/ijc.33483, PubMed 33529362
  18. Kotchetkov R, Susman D, Bhutani D, Broch K, Dispenzieri A, Buadi FK (2021)
    Reply to: Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein
    Int J Cancer, 149 (3), 743-744
    DOI 10.1002/ijc.33571, PubMed 33742687
  19. Kristiansen O, Sverre E, Peersen K, Fagerland MW, Gjertsen E, Gullestad L, Perk J, Dammen T, Husebye E, Vethe NT, Munkhaugen J (2021)
    The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease
    Atherosclerosis, 336, 23-29
    DOI 10.1016/j.atherosclerosis.2021.09.020, PubMed 34610521
  20. Kristiansen O, Vethe NT, Peersen K, Wang Fagerland M, Sverre E, Prunés Jensen E, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J (2021)
    Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
    Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
    DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361
  21. Kvaslerud AB, Santic K, Hussain AI, Auensen A, Fiane A, Skulstad H, Aaberge L, Gullestad L, Broch K (2021)
    Outcomes in asymptomatic, severe aortic stenosis
    PLoS One, 16 (4), e0249610
    DOI 10.1371/journal.pone.0249610, PubMed 33826652
  22. Massey RJ, Diep PP, Burman MM, Kvaslerud AB, Brinch L, Aakhus S, Gullestad L, Ruud E, Beitnes JO (2021)
    Impaired right ventricular function in long-term survivors of allogeneic haematopoietic stem-cell transplantation
    Open Heart, 8 (2)
    DOI 10.1136/openhrt-2021-001768, PubMed 34933961
  23. Munkhaugen J, Sverre E, Peersen K, Kristiansen O, Gjertsen E, Gullestad L, Erik Otterstad J (2021)
    Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?
    Eur J Prev Cardiol, 28 (8), e10-e11
    DOI 10.1177/2047487320923187, PubMed 33611511
  24. Olsen MB, Gregersen I, Sandanger Ø, Yang K, Sokolova M, Halvorsen BE, Gullestad L, Broch K, Aukrust P, Louwe MC (2021)
    Targeting the Inflammasome in Cardiovascular Disease
    JACC Basic Transl Sci, 7 (1), 84-98
    DOI 10.1016/j.jacbts.2021.08.006, PubMed 35128212
  25. Rafique M, Solberg OG, Gullestad L, Bendz B, Holm NR, Neghabat O, Dijkstra J, Nytrøen K, Rolid K, Lunde K (2021)
    A randomized clinical study using optical coherence tomography to evaluate the short-term effects of high-intensity interval training on cardiac allograft vasculopathy: a HITTS substudy
    Clin Transplant, 36 (1), e14488
    DOI 10.1111/ctr.14488, PubMed 34747048
  26. Traaen GM, Aakerøy L, Hunt TE, Øverland B, Bendz C, Sande LØ, Aakhus S, Fagerland MW, Steinshamn S, Anfinsen OG, Massey RJ, Broch K, Ueland T, Akre H, Loennechen JP, Gullestad L (2021)
    Effect of Continuous Positive Airway Pressure on Arrhythmia in Atrial Fibrillation and Sleep Apnea: A Randomized Controlled Trial
    Am J Respir Crit Care Med, 204 (5), 573-582
    DOI 10.1164/rccm.202011-4133OC, PubMed 33938787
  27. Ueland T, Abraityte A, Norum H, Varathalingam S, Gullestad L, Aukrust P, Andreassen AK (2021)
    Circulating regulators of the wingless pathway in precapillary pulmonary hypertension
    Respirology, 26 (6), 574-581
    DOI 10.1111/resp.14048, PubMed 33830565
  28. Ueland T, Gullestad L, Kou L, Young JB, Pfeffer MA, van Veldhuisen DJ, Swedberg K, Mcmurray JJV, Desai AS, Anand IS, Aukrust P (2021)
    Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF
    Clin Res Cardiol, 111 (4), 440-450
    DOI 10.1007/s00392-021-01944-6, PubMed 34611778
  29. Vergaro G, Gentile F, Meems LMG, Aimo A, Januzzi JL, Richards AM, Lam CSP, Latini R, Staszewsky L, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD et al. (2021)
    NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories
    JACC Heart Fail, 9 (9), 653-663
    DOI 10.1016/j.jchf.2021.05.014, PubMed 34246607
  30. Wyller VBB, Nygaard S, Christensen AH, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Døhlen G, Saul JP (2021)
    Functional evidence of low-pressure cardiopulmonary baroreceptor reinnervation 1 year after heart transplantation
    Eur J Appl Physiol, 121 (3), 915-927
    DOI 10.1007/s00421-020-04586-0, PubMed 33389144

Publications 2020

  1. Aimo A, Januzzi JL, Vergaro G, Richards AM, Lam CSP, Latini R, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD, Ling LH, Leong KTG, Yeo PSD et al. (2020)
    Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T
    Eur J Heart Fail, 22 (11), 2078-2088
    DOI 10.1002/ejhf.1701, PubMed 31919929
  2. Arain F, Abraityte A, Bogdanova M, Solberg OG, Michelsen AE, Lekva T, Aakhus S, Holm S, Halvorsen B, Finsen AV, Vinge LE, Nymo S, Espeland T, Ranheim T, Aukrust P, Vaage IJ, Auensen A, Gullestad L, Ueland T (2020)
    YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis
    Circ Heart Fail, 13 (10), e006643
    DOI 10.1161/CIRCHEARTFAILURE.119.006643, PubMed 32962417
  3. Bergh N, Gude E, Bartfay SE, K Andreassen A, Arora S, Dahlberg P, Dellgren G, Gullestad L, Gustafsson F, Karason K, Rådegran G, Bollano E, Andersson B (2020)
    Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
    ESC Heart Fail, 7 (2), 567-576
    DOI 10.1002/ehf2.12608, PubMed 32059083
  4. Broch K, Gude E, Karason K, Dellgren G, Rådegran G, Gjesdal G, Gustafsson F, Eiskjaer H, Lommi J, Pentikäinen M, Lemström KB, Andreassen AK, Gullestad L (2020)
    Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial
    Clin Transplant, 34 (9), e13984
    DOI 10.1111/ctr.13984, PubMed 32445429
  5. Broch K, Popperud T, Gude E, Fløisand Y, Antal EA, Bosse G, Jonsrud C, Hegard T, Skaara S, Elsais A (2020)
    A Middle-Aged Man Presenting With Progressive Heart Failure, Myopathy, and Monoclonal Gammopathy of Uncertain Significance
    JACC Case Rep, 2 (5), 785-789
    DOI 10.1016/j.jaccas.2020.02.024, PubMed 34317348
  6. Eriksen-Volnes T, Westheim A, Gullestad L, Slind EK, Grundtvig M (2020)
    β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry
    Biomed Hub, 5 (1), 9-18
    DOI 10.1159/000505474, PubMed 32775329
  7. George MJ, Kleveland O, Garcia-Hernandez J, Palmen J, Lovering R, Wiseth R, Aukrust P, Engmann J, Damås JK, Hingorani AD, Gullestad L, Casas JP, Ueland T (2020)
    Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform
    J Am Heart Assoc, 9 (12), e015628
    DOI 10.1161/JAHA.119.015628, PubMed 32515246
  8. Grundtvig M, Eriksen-Volnes T, Ørn S, Slind EK, Gullestad L (2020)
    6 min walk test is a strong independent predictor of death in outpatients with heart failure
    ESC Heart Fail, 7 (5), 2904-2911
    DOI 10.1002/ehf2.12900, PubMed 32677748
  9. Gude E, Hoel TN, Sørensen G, Broch K, Meyer A, Fiane AE (2020)
    Long-term continuous flow mechanical biventricular support: 9 years and counting
    Interact Cardiovasc Thorac Surg, 30 (1), 81-84
    DOI 10.1093/icvts/ivz231, PubMed 31580433
  10. Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators* (2020)
    Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study
    Transplantation, 104 (1), 154-164
    DOI 10.1097/TP.0000000000002702, PubMed 30893292
  11. Kristiansen S, Traaen GM, Øverland B, Plagemann T, Gullestad L, Akre H, Nikolaidis K, Aakerøy L, Hunt TE, Loennechen JP, Steinshamn S, Bendz C, Anfinsen OG, Goebel V (2020)
    Comparing manual and automatic scoring of sleep monitoring data from portable polygraphy
    J Sleep Res, 30 (2), e13036
    DOI 10.1111/jsr.13036, PubMed 32430962
  12. Kummen M, Solberg OG, Storm-Larsen C, Holm K, Ragnarsson A, Trøseid M, Vestad B, Skårdal R, Yndestad A, Ueland T, Svardal A, Berge RK, Seljeflot I, Gullestad L, Karlsen TH, Aaberge L, Aukrust P, Hov JR (2020)
    Rosuvastatin alters the genetic composition of the human gut microbiome
    Sci Rep, 10 (1), 5397
    DOI 10.1038/s41598-020-62261-y, PubMed 32214138
  13. Lekva T, Gullestad L, Broch K, Aukrust P, Andreassen AK, Ueland T (2020)
    Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertension
    Sci Rep, 10 (1), 18540
    DOI 10.1038/s41598-020-75654-w, PubMed 33122779
  14. Massey RJ, Diep PP, Ruud E, Burman MM, Kvaslerud AB, Brinch L, Aakhus S, Gullestad LL, Beitnes JO (2020)
    Left Ventricular Systolic Function in Long-Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation
    JACC CardioOncol, 2 (3), 460-471
    DOI 10.1016/j.jaccao.2020.06.011, PublikaID 352
  15. Mayerhofer CCK, Kummen M, Holm K, Broch K, Awoyemi A, Vestad B, Storm-Larsen C, Seljeflot I, Ueland T, Bohov P, Berge RK, Svardal A, Gullestad L, Yndestad A, Aukrust P, Hov JR, Trøseid M (2020)
    Low fibre intake is associated with gut microbiota alterations in chronic heart failure
    ESC Heart Fail, 7 (2), 456-466
    DOI 10.1002/ehf2.12596, PubMed 31978943
  16. Nelson LM, Andreassen AK, Arora S, Andersson B, Gude E, Eiskjaer H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F (2020)
    Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy
    Transpl Int, 33 (5), 517-528
    DOI 10.1111/tri.13577, PubMed 31958178
  17. Niyonzima N, Bakke SS, Gregersen I, Holm S, Sandanger Ø, Orrem HL, Sporsheim B, Ryan L, Kong XY, Dahl TB, Skjelland M, Sørensen KK, Rokstad AM, Yndestad A, Latz E, Gullestad L, Andersen GØ, Damås JK, Aukrust P, Mollnes TE, Halvorsen B, Espevik T (2020)
    Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis
    EBioMedicine, 60, 102985
    DOI 10.1016/j.ebiom.2020.102985, PubMed 32927275
  18. Nytrøen K, Rolid K, Yardley M, Gullestad L (2020)
    Effect of high-intensity interval training in young heart transplant recipients: results from two randomized controlled trials
    BMC Sports Sci Med Rehabil, 12, 35
    DOI 10.1186/s13102-020-00180-1, PubMed 32518655
  19. Peersen K, Otterstad JE, Sverre E, Perk J, Gullestad L, Moum T, Dammen T, Munkhaugen J (2020)
    Medical and Psychosocial Factors Associated With Low Physical Activity and Increasing Exercise Level After a Coronary Event
    J Cardiopulm Rehabil Prev, 40 (1), 35-40
    DOI 10.1097/HCR.0000000000000399, PubMed 30720643
  20. Rolid K, Andreassen AK, Yardley M, Gude E, Bjørkelund E, Authen AR, Grov I, Broch K, Gullestad L, Nytrøen K (2020)
    Long-term effects of high-intensity training vs moderate intensity training in heart transplant recipients: A 3-year follow-up study of the randomized-controlled HITTS study
    Am J Transplant, 20 (12), 3538-3549
    DOI 10.1111/ajt.16087, PubMed 32484261
  21. Rolid K, Andreassen AK, Yardley M, Gude E, Bjørkelund E, Authen AR, Grov I, Pettersen KI, Dall CH, Karason K, Broch K, Gullestad L, Nytrøen K (2020)
    High-intensity interval training and health-related quality of life in de novo heart transplant recipients - results from a randomized controlled trial
    Health Qual Life Outcomes, 18 (1), 283
    DOI 10.1186/s12955-020-01536-4, PubMed 32807179
  22. Sverre E, Peersen K, Perk J, Husebye E, Gullestad L, Dammen T, Otterstad JE, Munkhaugen J (2020)
    Challenges in coronary heart disease prevention - experiences from a long-term follow-up study in Norway
    Scand Cardiovasc J, 55 (2), 73-81
    DOI 10.1080/14017431.2020.1852308, PubMed 33274648
  23. Sverre E, Peersen K, Weedon-Fekjær H, Perk J, Gjertsen E, Husebye E, Gullestad L, Dammen T, Otterstad JE, Munkhaugen J (2020)
    Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population
    BMC Cardiovasc Disord, 20 (1), 61
    DOI 10.1186/s12872-020-01368-6, PubMed 32024471
  24. Tegn N, Eek C, Abdelnoor M, Aaberge L, Endresen K, Skårdal R, Berg ES, Gullestad L, Bendz B (2020)
    Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study
    Open Heart, 7 (2)
    DOI 10.1136/openhrt-2020-001256, PubMed 32719073
  25. Trøseid M, Andersen GØ, Broch K, Hov JR (2020)
    The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions
    EBioMedicine, 52, 102649
    DOI 10.1016/j.ebiom.2020.102649, PubMed 32062353
  26. Ueland T, Estensen ME, Grindheim G, Bollerslev J, Henriksen T, Aukrust P, Aakhus S, Gullestad L, Lekva T (2020)
    Elevated levels of the secreted wingless agonist R-spondin 3 in preeclamptic pregnancies
    J Hypertens, 38 (7), 1347-1354
    DOI 10.1097/HJH.0000000000002362, PubMed 31990902

Publications 2019

  1. Andreassen AK, Broch K, Eiskjær H, Karason K, Gude E, Mølbak D, Stueflotten W, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De-novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators (2019)
    Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial
    Transplantation, 103 (4), 781-788
    DOI 10.1097/TP.0000000000002445, PubMed 30211826
  2. Anstensrud AK, Woxholt S, Sharma K, Broch K, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L (2019)
    Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
    Open Heart, 6 (2), e001108
    DOI 10.1136/openhrt-2019-001108, PubMed 31673391
  3. Arora S, Ofstad AP, Ulimoen GR, Birkeland KI, Endresen K, Gullestad L, Johansen OE (2019)
    Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation
    Cardiovasc Diabetol, 18 (1), 26
    DOI 10.1186/s12933-019-0832-2, PubMed 30851727
  4. Bürker BS, Gullestad L, Gude E, Havik OE, Relbo Authen A, Grov I, Andreassen AK, Fiane AE, Haraldsen IR, Dew MA, Andersson S, Malt UF (2019)
    The Predictive Value of Depression in the Years After Heart Transplantation for Mortality During Long-Term Follow-Up
    Psychosom Med, 81 (6), 513-520
    DOI 10.1097/PSY.0000000000000702, PubMed 31033937
  5. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P et al. (2019)
    A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
    N Engl J Med, 382 (2), 120-129
    DOI 10.1056/NEJMoa1911425, PubMed 31733180
  6. Fosshaug LE, Colas RA, Anstensrud AK, Gregersen I, Nymo S, Sagen EL, Michelsen A, Vinge LE, Øie E, Gullestad L, Halvorsen B, Hansen TV, Aukrust P, Dalli J, Yndestad A (2019)
    Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
    EBioMedicine, 46, 264-273
    DOI 10.1016/j.ebiom.2019.07.024, PubMed 31345784
  7. Lunde NN, Gregersen I, Ueland T, Shetelig C, Holm S, Kong XY, Michelsen AE, Otterdal K, Yndestad A, Broch K, Gullestad L, Nyman TA, Bendz B, Eritsland J, Hoffmann P, Skagen K, Gonçalves I, Nilsson J, Grenegård M, Poreba M, Drag M, Seljeflot I, Sporsheim B, Espevik T, Skjelland M et al. (2019)
    Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages
    Atherosclerosis, 296, 74-82
    DOI 10.1016/j.atherosclerosis.2019.12.008, PubMed 31870625
  8. Mayerhofer CCK, Awoyemi A, Hov JR, Trøseid M, Broch K (2019)
    Reply: Potential risk associated with direct modulation of the gut flora in patients with heart failure
    ESC Heart Fail, 6 (3), 557-558
    DOI 10.1002/ehf2.12437, PubMed 31034162
  9. Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E (2019)
    Statin-associated muscle symptoms in coronary patients: design of a randomized study
    Scand Cardiovasc J, 53 (3), 162-168
    DOI 10.1080/14017431.2019.1612085, PubMed 31030568
  10. Nygaard S, Christensen AH, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Døhlen G, Godang K, Saul JP, Wyller VBB (2019)
    Autonomic cardiovascular control changes in recent heart transplant recipients lead to physiological limitations in response to orthostatic challenge and isometric exercise
    Eur J Appl Physiol, 119 (10), 2225-2236
    DOI 10.1007/s00421-019-04207-5, PubMed 31407088
  11. Nytrøen K, Rolid K, Andreassen AK, Yardley M, Gude E, Dahle DO, Bjørkelund E, Relbo Authen A, Grov I, Philip Wigh J, Have Dall C, Gustafsson F, Karason K, Gullestad L (2019)
    Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia
    Circulation, 139 (19), 2198-2211
    DOI 10.1161/CIRCULATIONAHA.118.036747, PubMed 30773030
  12. Nytrøen K, Rolid K, Gullestad L (2019)
    Response by Nytrøen et al to Letter Regarding Article, "Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia"
    Circulation, 140 (17), e735-e736
    DOI 10.1161/CIRCULATIONAHA.119.042458, PubMed 31634012
  13. Shahini N, Ueland T, Auensen A, Michelsen AE, Ludviksen JK, Hussain AI, Pettersen KI, Aakhus S, Espeland T, Lunde IG, Kirschfink M, Nilsson PH, Mollnes TE, Gullestad L, Aukrust P, Yndestad A, Louwe MC (2019)
    Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis
    J Immunol, 203 (7), 1973-1980
    DOI 10.4049/jimmunol.1801244, PubMed 31492744
  14. Solberg OG, Stavem K, Ragnarsson A, Beitnes JO, Skårdal R, Seljeflot I, Ueland T, Aukrust P, Gullestad L, Aaberge L (2019)
    Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study
    Catheter Cardiovasc Interv, 94 (5), 660-668
    DOI 10.1002/ccd.28157, PubMed 30790446
  15. Trøseid M, Mayerhofer CCK, Broch K, Arora S, Svardal A, Hov JR, Andreassen AK, Gude E, Karason K, Dellgren G, Berge RK, Gullestad L, Aukrust P, Ueland T (2019)
    The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection
    J Heart Lung Transplant, 38 (10), 1097-1103
    DOI 10.1016/j.healun.2019.06.003, PubMed 31301965
  16. Traaen GM, Øverland B, Aakerøy L, Hunt TE, Bendz C, Sande L, Aakhus S, Zaré H, Steinshamn S, Anfinsen OG, Loennechen JP, Gullestad L, Akre H (2019)
    Prevalence, risk factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation
    Int J Cardiol Heart Vasc, 26, 100447
    DOI 10.1016/j.ijcha.2019.100447, PubMed 32140547

Publications 2018

  1. Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T (2018)
    T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF
    Clin Res Cardiol, 108 (2), 133-141
    DOI 10.1007/s00392-018-1331-2, PubMed 30051179
  2. Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators (2018)
    Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients
    Circ Heart Fail, 11 (9), e004050
    DOI 10.1161/CIRCHEARTFAILURE.117.004050, PubMed 30354362
  3. Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L et al. (2018)
    Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
    Eur J Heart Fail, 20 (5), 888-895
    DOI 10.1002/ejhf.1146, PubMed 29488676
  4. Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL (2018)
    sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T
    J Am Coll Cardiol, 72 (19), 2309-2320
    DOI 10.1016/j.jacc.2018.08.2165, PubMed 30384887
  5. Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S (2018)
    [Espeland and co-workers respond]
    Tidsskr Nor Laegeforen, 138 (19)
    DOI 10.4045/tidsskr.18.0865, PubMed 30497251
  6. Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S (2018)
    Myocardial Fibrosis
    Tidsskr. Nor. Laegeforen., 138 (16), 1533-1539
  7. Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S (2018)
    Myocardial fibrosis
    Tidsskr Nor Laegeforen, 138 (16)
    DOI 10.4045/tidsskr.17.1027, PubMed 30344312
  8. Heier M, Ofstad AP, Borja MS, Brunborg C, Endresen K, Gullestad L, Birkeland KI, Johansen OE, Oda MN (2018)
    High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes
    Atherosclerosis, 282, 183-187
    DOI 10.1016/j.atherosclerosis.2018.07.005, PubMed 30017177
  9. Hussain AI, Auensen A, Brunborg C, Beitnes JO, Gullestad L, Pettersen KI (2018)
    Age-dependent morbidity and mortality outcomes after surgical aortic valve replacement
    Interact Cardiovasc Thorac Surg, 27 (5), 650-656
    DOI 10.1093/icvts/ivy154, PubMed 29746650
  10. Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, Holte E, Ryan L, Amundsen BH, Bendz B, Aakhus S, Espevik T, Halvorsen B, Mollnes TE, Wiseth R, Gullestad L, Aukrust P, Damås JK (2018)
    Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
    Int J Cardiol, 271, 1-7
    DOI 10.1016/j.ijcard.2018.04.136, PubMed 29961572
  11. Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, Ueland T, Yndestad A, Hov JR, Trøseid M (2018)
    Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts
    J Am Coll Cardiol, 71 (10), 1184-1186
    DOI 10.1016/j.jacc.2017.12.057, PubMed 29519360
  12. Kvaslerud AB, Hussain AI, Auensen A, Ueland T, Michelsen AE, Pettersen KI, Aukrust P, Mørkrid L, Gullestad L, Broch K (2018)
    Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis
    Open Heart, 5 (2), e000901
    DOI 10.1136/openhrt-2018-000901, PubMed 30613413
  13. Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K (2018)
    Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial
    ESC Heart Fail, 5 (5), 977-984
    DOI 10.1002/ehf2.12332, PubMed 30088346
  14. Munkhaugen J, Hjelmesæth J, Otterstad JE, Helseth R, Sollid ST, Gjertsen E, Gullestad L, Perk J, Moum T, Husebye E, Dammen T (2018)
    Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study
    BMC Cardiovasc Disord, 18 (1), 160
    DOI 10.1186/s12872-018-0896-z, PubMed 30075751
  15. Munkhaugen J, Otterstad JE, Dammen T, Gjertsen E, Moum T, Husebye E, Gullestad L (2018)
    The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event
    Eur J Prev Cardiol, 25 (9), 923-931
    DOI 10.1177/2047487318768940, PubMed 29635941
  16. Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE (2018)
    The follow-up after myocardial infarction - is it good enough?
    Tidsskr Nor Laegeforen, 138 (5)
    DOI 10.4045/tidsskr.17.1050, PubMed 29513442
  17. Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE (2018)
    The follow-up after myocardial infarction- is it good enough?
    Tidsskr. Nor. Laegeforen., 138 (5), 434-437
  18. Norum HM, Michelsen AE, Lekva T, Arora S, Otterdal K, Olsen MB, Kong XY, Gude E, Andreassen AK, Solbu D, Karason K, Dellgren G, Gullestad L, Aukrust P, Ueland T (2018)
    Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression
    Am J Transplant, 19 (4), 1050-1060
    DOI 10.1111/ajt.15141, PubMed 30312541
  19. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
    Heart Fail Rev, 23 (3), 303-323
    DOI 10.1007/s10741-018-9685-0, PubMed 29516230
  20. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    Response to the editor
    Heart Fail Rev (in press)
    DOI 10.1007/s10741-018-9723-y, PubMed 29968222
  21. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    Author's response to: letter to the editor
    Heart Fail Rev, 23 (5), 819
    DOI 10.1007/s10741-018-9728-6, PubMed 30043131
  22. Orrem HL, Nilsson PH, Pischke SE, Kleveland O, Yndestad A, Ekholt K, Damås JK, Espevik T, Bendz B, Halvorsen B, Gregersen I, Wiseth R, Andersen GØ, Ueland T, Gullestad L, Aukrust P, Barratt-Due A, Mollnes TE (2018)
    IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction
    Front Immunol, 9, 2035
    DOI 10.3389/fimmu.2018.02035, PubMed 30258440
  23. Rolid K, Andreassen AK, Yardley M, Bjørkelund E, Karason K, Wigh JP, Dall CH, Gustafsson F, Gullestad L, Nytrøen K (2018)
    Clinical features and determinants of VO2peak in de novo heart transplant recipients
    World J Transplant, 8 (5), 188-197
    DOI 10.5500/wjt.v8.i5.188, PubMed 30211027
  24. Tegn N, Abdelnoor M, Aaberge L, Hylen Ranhoff A, Endresen K, Gjertsen E, Skårdal R, Gullestad L, Bendz B, After Eighty study investigators (2018)
    Health-related quality of life in older patients with acute coronary syndrome randomised to an invasive or conservative strategy. The After Eighty randomised controlled trial
    Age Ageing, 47 (1), 42-47
    DOI 10.1093/ageing/afx121, PubMed 28985265
  25. Traaen GM, Aakerøy L, Hunt TE, Øverland B, Lyseggen E, Aukrust P, Ueland T, Helle-Valle T, Steinshamn S, Edvardsen T, Khiabani Zaré H, Aakhus S, Akre H, Anfinsen OG, Loennechen JP, Gullestad L (2018)
    Treatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trial
    Scand Cardiovasc J, 52 (6), 372-377
    DOI 10.1080/14017431.2019.1567933, PubMed 30638392
  26. Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N (2018)
    Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study
    ESC Heart Fail, 5 (6), 1052-1059
    DOI 10.1002/ehf2.12312, PubMed 30145817
  27. Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Aukrust P, Gullestad L, Halvorsen B, Yndestad A (2018)
    Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
    Open Heart, 5 (2), e000765
    DOI 10.1136/openhrt-2017-000765, PubMed 30258647
  28. Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Holven KB, Aukrust P, Gullestad L, Yndestad A, Halvorsen B (2018)
    Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction
    Int J Cardiol, 274, 348-350
    DOI 10.1016/j.ijcard.2018.06.093, PubMed 29961573
  29. Yardley M, Gullestad L, Nytrøen K (2018)
    Importance of physical capacity and the effects of exercise in heart transplant recipients
    World J Transplant, 8 (1), 1-12
    DOI 10.5500/wjt.v8.i1.1, PubMed 29507857

Publications 2017

  1. Abraityte A, Lunde IG, Askevold ET, Michelsen AE, Christensen G, Aukrust P, Yndestad A, Fiane A, Andreassen A, Aakhus S, Dahl CP, Gullestad L, Broch K, Ueland T (2017)
    Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy
    Sci Rep, 7 (1), 3490
    DOI 10.1038/s41598-017-03625-9, PubMed 28615692
  2. Abraityte A, Vinge LE, Askevold ET, Lekva T, Michelsen AE, Ranheim T, Alfsnes K, Fiane A, Aakhus S, Lunde IG, Dahl CP, Aukrust P, Christensen G, Gullestad L, Yndestad A, Ueland T (2017)
    Wnt5a is elevated in heart failure and affects cardiac fibroblast function
    J Mol Med (Berl), 95 (7), 767-777
    DOI 10.1007/s00109-017-1529-1, PubMed 28357477
  3. Auensen A, Hussain AI, Bendz B, Aaberge L, Falk RS, Walle-Hansen MM, Bye J, Andreassen J, Beitnes JO, Rein KA, Pettersen KI, Gullestad L (2017)
    Morbidity outcomes after surgical aortic valve replacement
    Open Heart, 4 (1), e000588
    DOI 10.1136/openhrt-2017-000588, PubMed 28674629
  4. Broch K, de Marchi SF, Massey R, Hisdal J, Aakhus S, Gullestad L, Urheim S (2017)
    Left Ventricular Contraction Pattern in Chronic Aortic Regurgitation and Preserved Ejection Fraction: Simultaneous Stress-Strain Analysis by Three-Dimensional Echocardiography
    J Am Soc Echocardiogr, 30 (4), 422-430.e2
    DOI 10.1016/j.echo.2016.11.012, PubMed 28065583
  5. Broch K, Leren IS, Saberniak J, Ueland T, Edvardsen T, Gullestad L, Haugaa KH (2017)
    Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy
    Biomarkers, 22 (3-4), 367-371
    DOI 10.1080/1354750X.2016.1278266, PubMed 28067540
  6. Bürker BS, Gude E, Gullestad L, Grov I, Relbo Authen A, Andreassen AK, Havik OE, Dew MA, Fiane AE, Haraldsen IR, Malt UF, Andersson S (2017)
    Cognitive function among long-term survivors of heart transplantation
    Clin Transplant, 31 (12)
    DOI 10.1111/ctr.13143, PubMed 29055147
  7. Bürker BS, Gullestad L, Gude E, Relbo Authen A, Grov I, Hol PK, Andreassen AK, Arora S, Dew MA, Fiane AE, Haraldsen IR, Malt UF, Andersson S (2017)
    Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens
    Clin Transplant, 31 (4)
    DOI 10.1111/ctr.12927, PubMed 28185318
  8. Gude E, Gullestad L, Andreassen AK (2017)
    Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
    Curr Opin Organ Transplant, 22 (3), 198-206
    DOI 10.1097/MOT.0000000000000409, PubMed 28463861
  9. Günther A, Andersen R, Gude E, Jakobsen J, Edvardsen T, Sandvik L, Abildgaard A, Aaberge L, Gullestad L (2017)
    The predictive value of coronary artery calcium detected by computed tomography in a prospective study on cardiac allograft vasculopathy in heart transplant patients
    Transpl Int, 31 (1), 82-91
    DOI 10.1111/tri.13057, PubMed 28865096
  10. Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, Damås JK, Gullestad L, Aukrust P, Wiseth R (2017)
    Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction
    Heart, 103 (19), 1521-1527
    DOI 10.1136/heartjnl-2016-310875, PubMed 28432157
  11. Hussain AI, Auensen A, Brunborg C, Aakhus S, Fiane A, Pettersen KI, Gullestad L (2017)
    Determinants and Outcome of Decision Making Among Patients with Severe Aortic Stenosis
    J Heart Valve Dis, 26 (4), 413-422
    PubMed 29302940
  12. Klaeboe LG, Haland TF, Leren IS, Ter Bekke RMA, Brekke PH, Røsjø H, Omland T, Gullestad L, Aakhus S, Haugaa KH, Edvardsen T (2017)
    Prognostic Value of Left Ventricular Deformation Parameters in Patients with Severe Aortic Stenosis: A Pilot Study of the Usefulness of Strain Echocardiography
    J Am Soc Echocardiogr, 30 (8), 727-735.e1
    DOI 10.1016/j.echo.2017.04.009, PubMed 28599826
  13. Mayerhofer CCK, Ueland T, Broch K, Vincent RP, Cross GF, Dahl CP, Aukrust P, Gullestad L, Hov JR, Trøseid M (2017)
    Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure
    J Card Fail, 23 (9), 666-671
    DOI 10.1016/j.cardfail.2017.06.007, PubMed 28688889
  14. Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, Gullestad L, Moum T, Dammen T, Husebye E (2017)
    Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients
    Eur J Prev Cardiol, 24 (9), 981-989
    DOI 10.1177/2047487317693134, PubMed 28196429
  15. Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjær H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F (2017)
    Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation
    Transplantation, 101 (11), 2793-2800
    DOI 10.1097/TP.0000000000001706, PubMed 28230646
  16. Norum HM, Broch K, Michelsen AE, Lunde IG, Lekva T, Abraityte A, Dahl CP, Fiane AE, Andreassen AK, Christensen G, Aakhus S, Aukrust P, Gullestad L, Ueland T (2017)
    The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy
    J Cardiovasc Transl Res, 10 (4), 401-410
    DOI 10.1007/s12265-017-9748-y, PubMed 28474304
  17. Nymo SH, Aukrust P, Kjekshus J, McMurray JJ, Cleland JG, Wikstrand J, Muntendam P, Wienhues-Thelen U, Latini R, Askevold ET, Gravning J, Dahl CP, Broch K, Yndestad A, Gullestad L, Ueland T, CORONA Study Group (2017)
    Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure
    JACC Heart Fail, 5 (4), 256-264
    DOI 10.1016/j.jchf.2017.01.008, PubMed 28359413
  18. Olsen MB, Hildrestrand GA, Scheffler K, Vinge LE, Alfsnes K, Palibrk V, Wang J, Neurauter CG, Luna L, Johansen J, Øgaard JDS, Ohm IK, Slupphaug G, Kuśnierczyk A, Fiane AE, Brorson SH, Zhang L, Gullestad L, Louch WE, Iversen PO, Østlie I, Klungland A, Christensen G, Sjaastad I, Sætrom P et al. (2017)
    NEIL3-Dependent Regulation of Cardiac Fibroblast Proliferation Prevents Myocardial Rupture
    Cell Rep, 18 (1), 82-92
    DOI 10.1016/j.celrep.2016.12.009, PubMed 28052262
  19. Peersen K, Munkhaugen J, Gullestad L, Dammen T, Moum T, Otterstad JE (2017)
    Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention
    Scand J Public Health, 45 (3), 269-276
    DOI 10.1177/1403494816688375, PubMed 28181463
  20. Peersen K, Munkhaugen J, Gullestad L, Liodden T, Moum T, Dammen T, Perk J, Otterstad JE (2017)
    The role of cardiac rehabilitation in secondary prevention after coronary events
    Eur J Prev Cardiol, 24 (13), 1360-1368
    DOI 10.1177/2047487317719355, PubMed 28664773
  21. Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Dellgren G, Solbu D, Arora S, Andreassen AK, Gullestad L (2017)
    Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)
    Clin Transplant, 31 (9)
    DOI 10.1111/ctr.13038, PubMed 28640529
  22. Rutkovskiy A, Sagave J, Czibik G, Baysa A, Zihlavnikova Enayati K, Hillestad V, Dahl CP, Fiane A, Gullestad L, Gravning J, Ahmed S, Attramadal H, Valen G, Vaage J (2017)
    Connective tissue growth factor and bone morphogenetic protein 2 are induced following myocardial ischemia in mice and humans
    Scand J Clin Lab Invest, 77 (5), 321-331
    DOI 10.1080/00365513.2017.1318447, PubMed 28460577
  23. Shahini N, Michelsen AE, Nilsson PH, Ekholt K, Gullestad L, Broch K, Dahl CP, Aukrust P, Ueland T, Mollnes TE, Yndestad A, Louwe MC (2017)
    The alternative complement pathway is dysregulated in patients with chronic heart failure
    Sci Rep, 7, 42532
    DOI 10.1038/srep42532, PubMed 28195242
  24. Sverre E, Otterstad JE, Gjertsen E, Gullestad L, Husebye E, Dammen T, Moum T, Munkhaugen J (2017)
    Medical and sociodemographic factors predict persistent smoking after coronary events
    BMC Cardiovasc Disord, 17 (1), 241
    DOI 10.1186/s12872-017-0676-1, PubMed 28877684
  25. Sverre E, Peersen K, Husebye E, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Dammen T, Munkhaugen J (2017)
    Unfavourable risk factor control after coronary events in routine clinical practice
    BMC Cardiovasc Disord, 17 (1), 40
    DOI 10.1186/s12872-016-0387-z, PubMed 28109259
  26. Sverre E, Peersen K, Otterstad JE, Gullestad L, Perk J, Gjertsen E, Moum T, Husebye E, Dammen T, Munkhaugen J (2017)
    Optimal blood pressure control after coronary events: the challenge remains
    J Am Soc Hypertens, 11 (12), 823-830
    DOI 10.1016/j.jash.2017.10.007, PubMed 29128603
  27. Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV (2017)
    Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study
    Eur J Heart Fail, 20 (2), 268-277
    DOI 10.1002/ejhf.988, PubMed 28960777
  28. Yardley M, Ueland T, Aukrust P, Michelsen A, Bjørkelund E, Gullestad L, Nytrøen K (2017)
    Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients
    Open Heart, 4 (2), e000635
    DOI 10.1136/openhrt-2017-000635, PubMed 29225901

Publications 2016

  1. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE investigators (2016)
    Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study
    Am J Transplant, 16 (4), 1238-47
    DOI 10.1111/ajt.13588, PubMed 26820618
  2. Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T (2016)
    Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)
    Biomarkers, 22 (3-4), 261-267
    DOI 10.1080/1354750X.2016.1204003, PubMed 27325138
  3. Broch K, Urheim S, Massey R, Stueflotten W, Fosså K, Hopp E, Aakhus S, Gullestad L (2016)
    Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation
    Int J Cardiol, 223, 688-692
    DOI 10.1016/j.ijcard.2016.08.237, PubMed 27568990
  4. Dhondup Y, Ueland T, Dahl CP, Askevold ET, Sandanger Ø, Fiane A, Ohm IK, Sjaastad I, Finsen AV, Wæhre A, Gullestad L, Aukrust P, Yndestad A, Vinge LE (2016)
    Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure
    J Card Fail, 22 (10), 823-8
    DOI 10.1016/j.cardfail.2016.06.013, PubMed 27349571
  5. Gullestad L, Eiskjaer H, Gustafsson F, Riise GC, Karason K, Dellgren G, Rådegran G, Hansson L, Gude E, Bjørtuft Ø, Jansson K, Schultz HH, Solbu D, Iversen M (2016)
    Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
    Transpl Int, 29 (7), 819-29
    DOI 10.1111/tri.12783, PubMed 27067532
  6. Hussain AI, Garratt AM, Brunborg C, Aakhus S, Gullestad L, Pettersen KI (2016)
    Eliciting Patient Risk Willingness in Clinical Consultations as a Means of Improving Decision-Making of Aortic Valve Replacement
    J Am Heart Assoc, 5 (3), e002828
    DOI 10.1161/JAHA.115.002828, PubMed 26994130
  7. Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T, Aakhus S, Damås JK, Aukrust P, Wiseth R, Gullestad L (2016)
    Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
    Eur Heart J, 37 (30), 2406-13
    DOI 10.1093/eurheartj/ehw171, PubMed 27161611
  8. Mirza K, Gustafsson F, Gullestad L, Arora S, Andersen C (2016)
    Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation
    Transpl Immunol, 38, 75-7
    DOI 10.1016/j.trim.2016.05.004, PubMed 27260644
  9. Munkhaugen J, Sverre E, Peersen K, Egge Ø, Gjertsen Eikeseth C, Gjertsen E, Gullestad L, Erik Otterstad J, Husebye E, Dammen T (2016)
    Patient characteristics and risk factors of participants and non-participants in the NOR-COR study
    Scand Cardiovasc J, 50 (5-6), 317-322
    DOI 10.1080/14017431.2016.1202445, PubMed 27323914
  10. Murbraech K, Holte E, Broch K, Smeland KB, Holte H, Rösner A, Lund MB, Dalen H, Kiserud C, Aakhus S (2016)
    Impaired Right Ventricular Function in Long-Term Lymphoma Survivors
    J Am Soc Echocardiogr, 29 (6), 528-36
    DOI 10.1016/j.echo.2016.02.014, PubMed 27038515
  11. Solberg OG, Stavem K, Ragnarsson A, Ioanes D, Arora S, Endresen K, Benth JŠ, Gullestad L, Gude E, Andreassen AK, Aaberge L (2016)
    Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial
    J Heart Lung Transplant, 35 (8), 1010-7
    DOI 10.1016/j.healun.2016.03.002, PubMed 27113960
  12. Soubrier M, Pei J, Durand F, Gullestad L, John A (2016)
    Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
    Rheumatol Ther, 4 (1), 133-149
    DOI 10.1007/s40744-016-0049-8, PubMed 27900570
  13. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Gullestad L, Bendz B (2016)
    [Not Available]
    Tidsskr Nor Laegeforen, 136 (16), 1324-5
    DOI 10.4045/tidsskr.16.0685, PubMed 27637033
  14. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E, Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B, After Eighty study investigators (2016)
    Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial
    Lancet, 387 (10023), 1057-1065
    DOI 10.1016/S0140-6736(15)01166-6, PubMed 26794722
  15. Yardley M, Gullestad L, Bendz B, Bjørkelund E, Rolid K, Arora S, Nytrøen K (2016)
    Long-term effects of high-intensity interval training in heart transplant recipients: A 5-year follow-up study of a randomized controlled trial
    Clin Transplant, 31 (1)
    DOI 10.1111/ctr.12868, PubMed 27865004

Publications 2015

  1. Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators (2015)
    The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial
    Am J Transplant, 15 (7), 1967-75
    DOI 10.1111/ajt.13214, PubMed 25783974
  2. Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T (2015)
    Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
    PLoS One, 10 (8), e0133970
    DOI 10.1371/journal.pone.0133970, PubMed 26288364
  3. Baysa A, Sagave J, Carpi A, Zaglia T, Campesan M, Dahl CP, Bilbija D, Troitskaya M, Gullestad L, Giorgio M, Mongillo M, Di Lisa F, Vaage JI, Valen G (2015)
    The p66ShcA adaptor protein regulates healing after myocardial infarction
    Basic Res Cardiol, 110 (2), 13
    DOI 10.1007/s00395-015-0470-0, PubMed 25680868
  4. Broch K, Andreassen AK, Hopp E, Leren TP, Scott H, Müller F, Aakhus S, Gullestad L (2015)
    Results of comprehensive diagnostic work-up in 'idiopathic' dilated cardiomyopathy
    Open Heart, 2 (1), e000271
    DOI 10.1136/openhrt-2015-000271, PubMed 26468400
  5. Broch K, Murbraech K, Ragnarsson A, Gude E, Andersen R, Fiane AE, Andreassen J, Aakhus S, Andreassen AK (2015)
    Echocardiographic evidence of right ventricular functional improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
    J Heart Lung Transplant, 35 (1), 80-86
    DOI 10.1016/j.healun.2015.08.007, PubMed 26476768
  6. Broch K, Murbræch K, Andreassen AK, Hopp E, Aakhus S, Gullestad L (2015)
    Contemporary Outcome in Patients With Idiopathic Dilated Cardiomyopathy
    Am J Cardiol, 116 (6), 952-9
    DOI 10.1016/j.amjcard.2015.06.022, PubMed 26233575
  7. Broch K, Urheim S, Lønnebakken MT, Stueflotten W, Massey R, Fosså K, Hopp E, Aakhus S, Gullestad L (2015)
    Controlled release metoprolol for aortic regurgitation: a randomised clinical trial
    Heart, 102 (3), 191-7
    DOI 10.1136/heartjnl-2015-308416, PubMed 26661319
  8. Cowie MR, Woehrle H, Oldenburg O, Damy T, van der Meer P, Erdman E, Metra M, Zannad F, Trochu JN, Gullestad L, Fu M, Böhm M, Auricchio A, Levy P (2015)
    Sleep-disordered Breathing in Heart Failure - Current State of the Art
    Card Fail Rev, 1 (1), 16-24
    DOI 10.15420/cfr.2015.01.01.16, PubMed 28785426
  9. De Blois J, Fagerland MW, Grundtvig M, Semb AG, Gullestad L, Westheim A, Hole T, Atar D, Agewall S (2015)
    ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry
    Eur Heart J Cardiovasc Pharmacother, 1 (1), 31-6
    DOI 10.1093/ehjcvp/pvu010, PubMed 27533962
  10. Dhondup Y, Sjaastad I, Scott H, Sandanger Ø, Zhang L, Haugstad SB, Aronsen JM, Ranheim T, Holmen SD, Alfsnes K, Ahmed MS, Attramadal H, Gullestad L, Aukrust P, Christensen G, Yndestad A, Vinge LE (2015)
    Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice
    PLoS One, 10 (10), e0139715
    DOI 10.1371/journal.pone.0139715, PubMed 26461521
  11. Estensen ME, Grindheim G, Remme EW, Godang K, Henriksen T, Aukrust P, Aakhus S, Gullestad L, Ueland T (2015)
    Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness
    Pregnancy Hypertens, 5 (4), 325-9
    DOI 10.1016/j.preghy.2015.09.003, PubMed 26597749
  12. Fosshaug LE, Dahl CP, Risnes I, Bohov P, Berge RK, Nymo S, Geiran O, Yndestad A, Gullestad L, Aukrust P, Vinge LE, Øie E (2015)
    Altered Levels of Fatty Acids and Inflammatory and Metabolic Mediators in Epicardial Adipose Tissue in Patients With Systolic Heart Failure
    J Card Fail, 21 (11), 916-23
    DOI 10.1016/j.cardfail.2015.07.014, PubMed 26231517
  13. Geir Solberg O, Aaberge L, Ragnarsson A, Aas M, Endresen K, Šaltytė Benth J, Gullestad L, Stavem K (2015)
    Comparison of simplified and comprehensive methods for assessing the index of microvascular resistance in heart transplant recipients
    Catheter Cardiovasc Interv, 87 (2), 283-90
    DOI 10.1002/ccd.26283, PubMed 26525162
  14. Hussain AI, Garratt AM, Beitnes JO, Gullestad L, Pettersen KI (2015)
    Validity of standard gamble utilities in patients referred for aortic valve replacement
    Qual Life Res, 25 (7), 1703-12
    DOI 10.1007/s11136-015-1186-1, PubMed 26603737
  15. Munkhaugen J, Sverre E, Peersen K, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Perk J, Husebye E, Dammen T (2015)
    The role of medical and psychosocial factors for unfavourable coronary risk factor control
    Scand Cardiovasc J, 50 (1), 1-8
    DOI 10.3109/14017431.2015.1111408, PubMed 26488672
  16. Norum HM, Gullestad L, Abraityte A, Broch K, Aakhus S, Aukrust P, Ueland T (2015)
    Increased Serum Levels of the Notch Ligand DLL1 are Associated with Diastolic Dysfunction, Reduced Exercise Capacity, and Adverse Outcome in Chronic Heart Failure
    J Card Fail, 22 (3), 218-23
    DOI 10.1016/j.cardfail.2015.07.012, PubMed 26211721
  17. Nymo SH, Ueland T, Askevold E, Dahl CP, Gullestad L, Aukrust P, Yndestad A (2015)
    Circulating nucleosomes in chronic heart failure
    Int J Cardiol, 203, 742-3
    DOI 10.1016/j.ijcard.2015.10.219, PubMed 26595779
  18. Nytrøen K, Yardley M, Rolid K, Bjørkelund E, Karason K, Wigh JP, Dall CH, Arora S, Aakhus S, Lunde K, Solberg OG, Gustafsson F, Prescott EI, Gullestad L (2015)
    Design and rationale of the HITTS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia
    Am Heart J, 172, 96-105
    DOI 10.1016/j.ahj.2015.10.011, PubMed 26856221
  19. Ofstad AP, Urheim S, Dalen H, Orvik E, Birkeland KI, Gullestad L, W Fagerland M, Johansen OE, Aakhus S (2015)
    Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls
    J Diabetes, 7 (6), 779-90
    DOI 10.1111/1753-0407.12239, PubMed 25350248
  20. Røysland R, Røsjø H, Høiseth AD, Gullestad L, Badr P, Kravdal G, Omland T (2015)
    Osteoprotegerin concentrations in patients with suspected reversible myocardial ischemia: observations from the Akershus Cardiac Examination (ACE) 1 Study
    Cytokine, 73 (1), 122-7
    DOI 10.1016/j.cyto.2015.01.020, PubMed 25748834
  21. Schurgers LJ, Burgmaier M, Ueland T, Schutters K, Aakhus S, Hofstra L, Gullestad L, Aukrust P, Hellmich M, Narula J, Reutelingsperger CP (2015)
    Circulating annexin A5 predicts mortality in patients with heart failure
    J Intern Med, 279 (1), 89-97
    DOI 10.1111/joim.12396, PubMed 26223343
  22. Ulimoen GR, Ofstad AP, Endresen K, Gullestad L, Johansen OE, Borthne A (2015)
    Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--a cross-sectional study
    BMC Cardiovasc Disord, 15, 147
    DOI 10.1186/s12872-015-0143-9, PubMed 26573616
  23. Yardley M, Havik OE, Grov I, Relbo A, Gullestad L, Nytrøen K (2015)
    Peak oxygen uptake and self-reported physical health are strong predictors of long-term survival after heart transplantation
    Clin Transplant, 30 (2), 161-9
    DOI 10.1111/ctr.12672, PubMed 26589579

Publications 2014

  1. Abraityte A, Gullestad L, Askevold ET, Nymo S, Dahl CP, Aakhus S, Aukrust P, Ueland T (2014)
    The Notch ligand Delta-like 1 is elevated and associated with mortality in patients with symptomatic aortic stenosis
    Int J Cardiol, 180, 18-20
    DOI 10.1016/j.ijcard.2014.11.111, PubMed 25438200
  2. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Sigurdardottir V, Arora S, Dellgren G, Gullestad L, SCHEDULE Investigators (2014)
    Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial
    Am J Transplant, 14 (8), 1828-38
    DOI 10.1111/ajt.12809, PubMed 25041227
  3. Apelland T, Gude E, Strøm EH, Gullestad L, Eiklid KL, Månsson JE, Reinholt FP, Houge G, Dahl CP, Almaas VM, Heiberg A (2014)
    Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease
    Heart, 100 (22), 1793-8
    DOI 10.1136/heartjnl-2014-305616, PubMed 25031264
  4. Arora S, Gullestad L (2014)
    The challenge of allograft vasculopathy in cardiac transplantation
    Curr Opin Organ Transplant, 19 (5), 508-14
    DOI 10.1097/MOT.0000000000000112, PubMed 25144667
  5. Askevold ET, Aukrust P, Nymo SH, Lunde IG, Kaasbøll OJ, Aakhus S, Florholmen G, Ohm IK, Strand ME, Attramadal H, Fiane A, Dahl CP, Finsen AV, Vinge LE, Christensen G, Yndestad A, Gullestad L, Latini R, Masson S, Tavazzi L, GISSI-HF Investigators, Ueland T (2014)
    The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure
    J Intern Med, 275 (6), 621-30
    DOI 10.1111/joim.12175, PubMed 24330105
  6. Askevold ET, Gullestad L, Dahl CP, Yndestad A, Ueland T, Aukrust P (2014)
    Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure
    Curr Heart Fail Rep, 11 (2), 146-55
    DOI 10.1007/s11897-014-0185-9, PubMed 24477903
  7. Bilbija D, Elmabsout AA, Sagave J, Haugen F, Bastani N, Dahl CP, Gullestad L, Sirsjö A, Blomhoff R, Valen G (2014)
    Expression of retinoic acid target genes in coronary artery disease
    Int J Mol Med, 33 (3), 677-86
    DOI 10.3892/ijmm.2014.1623, PubMed 24424466
  8. Bot I, Daissormont IT, Zernecke A, van Puijvelde GH, Kramp B, de Jager SC, Sluimer JC, Manca M, Hérias V, Westra MM, Bot M, van Santbrink PJ, van Berkel TJ, Su L, Skjelland M, Gullestad L, Kuiper J, Halvorsen B, Aukrust P, Koenen RR, Weber C, Biessen EA (2014)
    CXCR4 blockade induces atherosclerosis by affecting neutrophil function
    J Mol Cell Cardiol, 74, 44-52
    DOI 10.1016/j.yjmcc.2014.04.021, PubMed 24816217
  9. Broch K, Al-Ani A, Gude E, Gullestad L, Aakhus S (2014)
    Echocardiographic evaluation of left ventricular filling pressure in heart transplant recipients
    Scand Cardiovasc J, 48 (6), 349-56
    DOI 10.3109/14017431.2014.981579, PubMed 25414078
  10. Broch K, Andreassen AK, Ueland T, Michelsen AE, Stueflotten W, Aukrust P, Aakhus S, Gullestad L (2014)
    Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure
    Int J Cardiol, 179, 378-84
    DOI 10.1016/j.ijcard.2014.11.003, PubMed 25464491
  11. Broch K, Askevold ET, Gjertsen E, Ueland T, Yndestad A, Godang K, Stueflotten W, Andreassen J, Svendsmark R, Smith HJ, Aakhus S, Aukrust P, Gullestad L (2014)
    The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial
    PLoS One, 9 (2), e89732
    DOI 10.1371/journal.pone.0089732, PubMed 24586994
  12. Cornu C, Dufays C, Gaillard S, Gueyffier F, Redonnet M, Sebbag L, Roussoulières A, Gleissner CA, Groetzner J, Lehmkuhl HB, Potena L, Gullestad L, Cantarovich M, Boissonnat P (2014)
    Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis
    Br J Clin Pharmacol, 78 (1), 24-32
    DOI 10.1111/bcp.12289, PubMed 24251918
  13. Finsen AV, Ueland T, Sjaastad I, Ranheim T, Ahmed MS, Dahl CP, Askevold ET, Aakhus S, Husberg C, Fiane AE, Lipp M, Gullestad L, Christensen G, Aukrust P, Yndestad A (2014)
    The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling
    PLoS One, 9 (11), e112172
    DOI 10.1371/journal.pone.0112172, PubMed 25398010
  14. Gustafsson F, Gude E, Sigurdardottir V, Aukrust P, Solbu D, Goetze JP, Gullestad L (2014)
    Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels
    Biomark Med, 8 (2), 239-45
    DOI 10.2217/bmm.13.95, PubMed 24521021
  15. Halvorsen B, Smedbakken LM, Michelsen AE, Skjelland M, Bjerkeli V, Sagen EL, Taskén K, Bendz B, Gullestad L, Holm S, Biessen EA, Aukrust P (2014)
    Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13
    Atherosclerosis, 234 (2), 352-9
    DOI 10.1016/j.atherosclerosis.2014.03.021, PubMed 24732574
  16. Hasselberg NE, Haugaa KH, Sarvari SI, Gullestad L, Andreassen AK, Smiseth OA, Edvardsen T (2014)
    Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction
    Eur Heart J Cardiovasc Imaging, 16 (2), 217-24
    DOI 10.1093/ehjci/jeu277, PubMed 25552469
  17. Holm T, Færestrand S, Larsen AI, Jønland KB, Gullestad L, Dickstein K, Köpp U, Sirnes PA, Tande P, Steen T, Kongsgård E (2014)
    [Cardiac resynchronization therapy in heart failure--Norwegian guidelines]
    Tidsskr Nor Laegeforen, 134 (10), E1-17
    DOI 10.4045/tidsskr.13.0628, PubMed 24865746
  18. Ofstad AP, Johansen OE, Gullestad L, Birkeland KI, Orvik E, Fagerland MW, Urheim S, Aakhus S (2014)
    Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study
    Am Heart J, 168 (3), 280-288.e2
    DOI 10.1016/j.ahj.2014.03.026, PubMed 25173538
  19. Perez-Moreno AC, Jhund PS, Macdonald MR, Petrie MC, Cleland JG, Böhm M, van Veldhuisen DJ, Gullestad L, Wikstrand J, Kjekshus J, Lewsey JD, McMurray JJ (2014)
    Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
    JACC Heart Fail, 2 (2), 187-97
    DOI 10.1016/j.jchf.2014.01.001, PubMed 24720928
  20. Perez AC, Jhund PS, Stott DJ, Gullestad L, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, McMurray JJ (2014)
    Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure)
    JACC Heart Fail, 2 (1), 35-40
    DOI 10.1016/j.jchf.2013.07.008, PubMed 24622117
  21. Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ (2014)
    Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)
    JACC Heart Fail, 2 (3), 289-97
    DOI 10.1016/j.jchf.2013.12.007, PubMed 24952697
  22. Solberg OG, Ragnarsson A, Kvarsnes A, Endresen K, Kongsgard E, Aakhus S, Gullestad L, Stavem K, Aaberge L (2014)
    Reference interval for the index of coronary microvascular resistance
    EuroIntervention, 9 (9), 69-75
    DOI 10.4244/EIJV919A181
  23. Solberg OG, Ragnarsson A, Kvarsnes A, Endresen K, Kongsgård E, Aakhus S, Gullestad L, Stavem K, Aaberge L (2014)
    Reference interval for the index of coronary microvascular resistance
    EuroIntervention, 9 (9), 1069-75
    DOI 10.4244/EIJV9I9A181, PubMed 24457279
  24. Trøseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, Aakhus S, Gude E, Bjørndal B, Halvorsen B, Karlsen TH, Aukrust P, Gullestad L, Berge RK, Yndestad A (2014)
    Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure
    J Intern Med, 277 (6), 717-26
    DOI 10.1111/joim.12328, PubMed 25382824
  25. Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Block D, Zaugg C, Gullestad L (2014)
    Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial
    J Card Fail, 21 (2), 153-9
    DOI 10.1016/j.cardfail.2014.10.016, PubMed 25451704
  26. Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Wienhues-Thelen UH, Block D, Zaugg C, Gullestad L (2014)
    Predictive value of endostatin in chronic heart failure patients with poor kidney function
    Cardiology, 130 (1), 17-22
    DOI 10.1159/000368220, PubMed 25428583
  27. Ueland T, Gullestad L, Nymo SH, Yndestad A, Aukrust P, Askevold ET (2014)
    Inflammatory cytokines as biomarkers in heart failure
    Clin Chim Acta, 443, 71-7
    DOI 10.1016/j.cca.2014.09.001, PubMed 25199849
  28. Wu X, Sagave J, Rutkovskiy A, Haugen F, Baysa A, Nygård S, Czibik G, Dahl CP, Gullestad L, Vaage J, Valen G (2014)
    Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart
    Life Sci, 97 (2), 145-54
    DOI 10.1016/j.lfs.2013.12.030, PubMed 24398041

Publications 2013

  1. Dahl CP, Aukrust P, Nymo SH, Kjekshus J, Cleland JG, McMurray JJ, Wikstrand J, Gullestad L, Ueland T (2013)
    Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure
    Int J Cardiol, 168 (4), 4427-9
    DOI 10.1016/j.ijcard.2013.05.008, PubMed 23714594
  2. Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL, STICH Investigators (2013)
    Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease
    Circ Heart Fail, 6 (3), 443-50
    DOI 10.1161/CIRCHEARTFAILURE.112.000130, PubMed 23515275
  3. Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J, CORONA Study Group (2013)
    Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial
    Circ Heart Fail, 7 (1), 96-103
    DOI 10.1161/CIRCHEARTFAILURE.113.000450, PubMed 24284025
  4. Gregersen I, Skjelland M, Holm S, Holven KB, Krogh-Sørensen K, Russell D, Askevold ET, Dahl CP, Ørn S, Gullestad L, Mollnes TE, Ueland T, Aukrust P, Halvorsen B (2013)
    Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis
    PLoS One, 8 (8), e72769
    DOI 10.1371/journal.pone.0072769, PubMed 24023645
  5. Karlson BW, Dellborg M, Gullestad L, Aberg J, Sugg J, Herlitz J (2013)
    A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study
    Cardiology, 127 (2), 73-82
    DOI 10.1159/000355003, PubMed 24247812
  6. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L, Heart Failure Association of the European Society of Cardiology (HFA) (2013)
    EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)
    Eur J Heart Fail, 15 (7), 808-17
    DOI 10.1093/eurjhf/hft050, PubMed 23537547
  7. Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, Yndestad A, Gullestad L, Aukrust P (2013)
    Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA
    Eur J Heart Fail, 16 (1), 68-75
    DOI 10.1093/eurjhf/hft125, PubMed 23918775
  8. Nytrøen K, Gullestad L (2013)
    Effect of exercise in heart transplant recipients
    Am J Transplant, 13 (2), 527
    DOI 10.1111/ajt.12046, PubMed 23356900
  9. Nytrøen K, Gullestad L (2013)
    [Exercise after heart transplantation--old principles needs reevaluation]
    Tidsskr Nor Laegeforen, 133 (19), 2030-1
    DOI 10.4045/tidsskr.13.0903, PubMed 24129530
  10. Nytrøen K, Gullestad L (2013)
    Exercise after heart transplantation: An overview
    World J Transplant, 3 (4), 78-90
    DOI 10.5500/wjt.v3.i4.78, PubMed 24392312
  11. Nytrøen K, Rustad LA, Erikstad I, Aukrust P, Ueland T, Lekva T, Gude E, Wilhelmsen N, Hervold A, Aakhus S, Gullestad L, Arora S (2013)
    Effect of high-intensity interval training on progression of cardiac allograft vasculopathy
    J Heart Lung Transplant, 32 (11), 1073-80
    DOI 10.1016/j.healun.2013.06.023, PubMed 23906899
  12. Ofstad AP, Gullestad L, Orvik E, Aakhus S, Endresen K, Ueland T, Aukrust P, Fagerland MW, Birkeland KI, Johansen OE (2013)
    Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study
    Cardiovasc Diabetol, 12, 126
    DOI 10.1186/1475-2840-12-126, PubMed 23987834
  13. Prohászka Z, Munthe-Fog L, Ueland T, Gombos T, Yndestad A, Förhécz Z, Skjoedt MO, Pozsonyi Z, Gustavsen A, Jánoskuti L, Karádi I, Gullestad L, Dahl CP, Askevold ET, Füst G, Aukrust P, Mollnes TE, Garred P (2013)
    Association of ficolin-3 with severity and outcome of chronic heart failure
    PLoS One, 8 (4), e60976
    DOI 10.1371/journal.pone.0060976, PubMed 23596511
  14. Robertsen I, Falck P, Andreassen AK, Næss NK, Lunder N, Christensen H, Gullestad L, Asberg A (2013)
    Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients
    Transplant Res, 2 (1), 5
    DOI 10.1186/2047-1440-2-5, PubMed 23566530
  15. Rustad LA, Nytrøen K, Andreassen A, Geiran O, Endresen K, Gullestad L, Aakhus S, Amundsen BH (2013)
    Heart transplant systolic and diastolic function is impaired by prolonged pretransplant graft ischaemic time and high donor age: an echocardiographic study
    Eur J Cardiothorac Surg, 44 (2), e97-104
    DOI 10.1093/ejcts/ezt233, PubMed 23657552
  16. Strand ME, Herum KM, Rana ZA, Skrbic B, Askevold ET, Dahl CP, Vistnes M, Hasic A, Kvaløy H, Sjaastad I, Carlson CR, Tønnessen T, Gullestad L, Christensen G, Lunde IG (2013)
    Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart
    FEBS J, 280 (10), 2228-47
    DOI 10.1111/febs.12161, PubMed 23374111
  17. Ueland T, Nymo SH, Latini R, McMurray JJ, Kjekshus J, Yndestad A, Fucili A, Grosu A, Masson S, Maggioni AP, Gullestad L, Aukrust P, Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial, Investigators of the GISSI-Heart Failure (GISSI-HF) trial (2013)
    CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials
    Eur J Heart Fail, 15 (7), 747-55
    DOI 10.1093/eurjhf/hft031, PubMed 23487539
  18. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA (2013)
    Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH
    Circ Heart Fail, 6 (2), 219-26
    DOI 10.1161/CIRCHEARTFAILURE.112.000129, PubMed 23395934

Publications 2012

  1. Arora S, Erikstad I, Ueland T, Sigurdardottir V, Ekmehag B, Jansson K, Eiskjaer H, Bøtker HE, Mortensen SA, Saunamaki K, Gude E, Ragnarsson A, Solbu D, Aukrust P, Gullestad L (2012)
    Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial
    Am J Transplant, 12 (10), 2700-9
    DOI 10.1111/j.1600-6143.2012.04234.x, PubMed 22958738
  2. Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L (2012)
    Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate
    J Heart Lung Transplant, 31 (3), 259-65
    DOI 10.1016/j.healun.2011.12.010, PubMed 22333403
  3. Arora S, Aarones M, Aakhus S, Skaardal R, Aass H, Aukrust P, Kongsgaard E, Gullestad L (2012)
    Peak oxygen uptake during cardiopulmonary exercise testing determines response to cardiac resynchronization therapy
    J Cardiol, 60 (3), 228-35
    DOI 10.1016/j.jjcc.2012.03.004, PubMed 22542140
  4. Askevold ET, Gullestad L, Aakhus S, Ranheim T, Tønnessen T, Solberg OG, Aukrust P, Ueland T (2012)
    Secreted Wnt modulators in symptomatic aortic stenosis
    J Am Heart Assoc, 1 (6), e002261
    DOI 10.1161/JAHA.112.002261, PubMed 23316316
  5. Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ, Aukrust P, Gullestad L (2012)
    Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
    Circ Heart Fail, 6 (1), 91-8
    DOI 10.1161/CIRCHEARTFAILURE.112.972653, PubMed 23230311
  6. Broch K, Eek C, Wergeland R, Ueland T, Skårdal R, Aukrust P, Skulstad H, Gullestad L (2012)
    NT-proBNP predicts myocardial recovery after non-ST-elevation acute coronary syndrome
    Scand Cardiovasc J, 46 (2), 65-71
    DOI 10.3109/14017431.2011.652981, PubMed 22191851
  7. Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Cleland JG, Aukrust P, Gullestad L (2012)
    Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology
    Eur J Heart Fail, 14 (3), 268-77
    DOI 10.1093/eurjhf/hfs006, PubMed 22302661
  8. Broch K, Ueland T, Yndestad A, Aukrust P, Gullestad L (2012)
    Heart failure biomarkers: focus on interleukin-1 receptor-like 1-based blood tests
    Drugs Today (Barc), 48 (7), 479-91
    DOI 10.1358/dot.2012.48.7.1811719, PubMed 22844659
  9. Erikssen G, Liestøl K, Gullestad L, Haugaa KH, Bendz B, Amlie JP (2012)
    The terminal part of the QT interval (T peak to T end): a predictor of mortality after acute myocardial infarction
    Ann Noninvasive Electrocardiol, 17 (2), 85-94
    DOI 10.1111/j.1542-474X.2012.00493.x, PubMed 22537325
  10. Gullestad L, Orn S, Dickstein K, Eek C, Edvardsen T, Aakhus S, Askevold ET, Michelsen A, Bendz B, Skårdal R, Smith HJ, Yndestad A, Ueland T, Aukrust P (2012)
    Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction
    Int J Cardiol, 168 (1), 212-8
    DOI 10.1016/j.ijcard.2012.09.092, PubMed 23046599
  11. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Böhm M, van Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P, CORONA Study Group (2012)
    Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
    Eur Heart J, 33 (18), 2290-6
    DOI 10.1093/eurheartj/ehs077, PubMed 22513778
  12. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P (2012)
    The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
    Am Heart J, 164 (6), 878-83
    DOI 10.1016/j.ahj.2012.08.021, PubMed 23194488
  13. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012)
    Inflammatory cytokines in heart failure: mediators and markers
    Cardiology, 122 (1), 23-35
    DOI 10.1159/000338166, PubMed 22699305
  14. Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vårdal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L, Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials (2012)
    Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
    Eur J Heart Fail, 14 (9), 992-9
    DOI 10.1093/eurjhf/hfs092, PubMed 22740508
  15. Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A (2012)
    The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*
    J Intern Med, 271 (5), 436-43
    DOI 10.1111/j.1365-2796.2011.02503.x, PubMed 22211640
  16. Nytrøen K, Rustad LA, Aukrust P, Ueland T, Hallén J, Holm I, Rolid K, Lekva T, Fiane AE, Amlie JP, Aakhus S, Gullestad L (2012)
    High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients
    Am J Transplant, 12 (11), 3134-42
    DOI 10.1111/j.1600-6143.2012.04221.x, PubMed 22900793
  17. Nytrøen K, Rustad LA, Gude E, Hallén J, Fiane AE, Rolid K, Holm I, Aakhus S, Gullestad L (2012)
    Muscular exercise capacity and body fat predict VO(2peak) in heart transplant recipients
    Eur J Prev Cardiol, 21 (1), 21-9
    DOI 10.1177/2047487312450540, PubMed 22659939
  18. Rustad LA, Nytrøen K, Amundsen BH, Gullestad L, Aakhus S (2012)
    One year of high-intensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: a randomised controlled trial
    Eur J Prev Cardiol, 21 (2), 181-91
    DOI 10.1177/2047487312469477, PubMed 23185084
  19. Rutkovskiy A, Stensløkken KO, Mariero LH, Skrbic B, Amiry-Moghaddam M, Hillestad V, Valen G, Perreault MC, Ottersen OP, Gullestad L, Dahl CP, Vaage J (2012)
    Aquaporin-4 in the heart: expression, regulation and functional role in ischemia
    Basic Res Cardiol, 107 (5), 280
    DOI 10.1007/s00395-012-0280-6, PubMed 22777185
  20. Sarvari SI, Gjesdal O, Gude E, Arora S, Andreassen AK, Gullestad L, Geiran O, Edvardsen T (2012)
    Early postoperative left ventricular function by echocardiographic strain is a predictor of 1-year mortality in heart transplant recipients
    J Am Soc Echocardiogr, 25 (9), 1007-14
    DOI 10.1016/j.echo.2012.05.010, PubMed 22727199
  21. Sikkeland LI, Dahl CP, Ueland T, Andreassen AK, Gude E, Edvardsen T, Holm T, Yndestad A, Gullestad L, Kongerud J, Aukrust P, Øie E (2012)
    Increased levels of inflammatory cytokines and endothelin-1 in alveolar macrophages from patients with chronic heart failure
    PLoS One, 7 (5), e36815
    DOI 10.1371/journal.pone.0036815, PubMed 22615818
  22. Smedbakken LM, Halvorsen B, Daissormont I, Ranheim T, Michelsen AE, Skjelland M, Sagen EL, Folkersen L, Krohg-Sørensen K, Russell D, Holm S, Ueland T, Fevang B, Hedin U, Yndestad A, Gullestad L, Hansson GK, Biessen EA, Aukrust P (2012)
    Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis - Potential role in plaque stabilization
    Atherosclerosis, 224 (1), 266-73
    DOI 10.1016/j.atherosclerosis.2012.06.071, PubMed 22840692
  23. Solberg OG, Ueland T, Wergeland R, Dahl CP, Aakhus S, Aukrust P, Gullestad L (2012)
    High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis
    Scand Cardiovasc J, 46 (5), 278-85
    DOI 10.3109/14017431.2012.687836, PubMed 22545649
  24. Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE (2012)
    Activin A and cardiovascular disease in type 2 diabetes mellitus
    Diab Vasc Dis Res, 9 (3), 234-7
    DOI 10.1177/1479164111431171, PubMed 22234949
  25. Ueland T, Svardal A, Øie E, Askevold ET, Nymoen SH, Bjørndal B, Dahl CP, Gullestad L, Berge RK, Aukrust P (2012)
    Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis
    Int J Cardiol, 167 (5), 1892-9
    DOI 10.1016/j.ijcard.2012.04.150, PubMed 22622056
  26. Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P (2012)
    TNF revisited: osteoprotegerin and TNF-related molecules in heart failure
    Curr Heart Fail Rep, 9 (2), 92-100
    DOI 10.1007/s11897-012-0088-6, PubMed 22453763
  27. Waldum B, Westheim AS, Sandvik L, Flønæs B, Grundtvig M, Gullestad L, Hole T, Os I (2012)
    Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry
    J Am Coll Cardiol, 59 (4), 371-8
    DOI 10.1016/j.jacc.2011.10.864, PubMed 22261159
  28. Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Øie E, Vinge LE, Sjaastad I, Sandanger Ø, Ranheim T, Dickstein K, Kjekshus J, Damås JK, Fiane AE, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P (2012)
    The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure
    PLoS One, 7 (3), e33038
    DOI 10.1371/journal.pone.0033038, PubMed 22427939

Publications 2011

  1. Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L (2011)
    Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial
    Transplantation, 92 (2), 235-43
    DOI 10.1097/TP.0b013e31822057f1, PubMed 21677600
  2. Egstrup K, Bergfeldt L, Duris T, Gullestad L, Kochmanski M, Kuśnierz B, Nielsen T, Sawicki S, Aunes-Jansson M, Edvardsson N, Frison L, Johansson S, Berggren A (2011)
    QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial
    Am J Cardiovasc Drugs, 11 (3), 199-208
    DOI 10.2165/11591750-000000000-00000, PubMed 21619383
  3. Fosshaug LE, Berge RK, Beitnes JO, Berge K, Vik H, Aukrust P, Gullestad L, Vinge LE, Øie E (2011)
    Krill oil attenuates left ventricular dilatation after myocardial infarction in rats
    Lipids Health Dis, 10, 245
    DOI 10.1186/1476-511X-10-245, PubMed 22206454
  4. Gullestad L, Pernow J, Bjurö T, Aaberge L, Skårdal R, Kjekshus E, Høglund L, Mellgård AJ, Wahlquist I, Ablad B (2011)
    Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease
    Scand Cardiovasc J, 46 (1), 23-31
    DOI 10.3109/14017431.2011.624195, PubMed 22017530
  5. Nytrøen K, Myers J, Chan KN, Geiran OR, Gullestad L (2011)
    Chronotropic responses to exercise in heart transplant recipients: 1-yr follow-up
    Am J Phys Med Rehabil, 90 (7), 579-88
    DOI 10.1097/PHM.0b013e31821f711d, PubMed 21765276
  6. Tveit A, Flonaes B, Aaser E, Korneliussen K, Froland G, Gullestad L, Grundtvig M (2011)
    No impact of atrial fibrillation on mortality risk in optimally treated heart failure patients
    Clin Cardiol, 34 (9), 537-42
    DOI 10.1002/clc.20939, PubMed 21796642
  7. Ueland T, Aukrust P, Broch K, Aakhus S, Skårdal R, Muntendam P, Gullestad L (2011)
    Galectin-3 in heart failure: high levels are associated with all-cause mortality
    Int J Cardiol, 150 (3), 361-4
    DOI 10.1016/j.ijcard.2011.05.081, PubMed 21641051
  8. Ueland T, Aukrust P, Dahl CP, Husebye T, Solberg OG, Tønnessen T, Aakhus S, Gullestad L (2011)
    Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis
    J Intern Med, 270 (5), 452-60
    DOI 10.1111/j.1365-2796.2011.02393.x, PubMed 21623962
  9. Ueland T, Dahl CP, Gullestad L, Aakhus S, Broch K, Skårdal R, Vermeer C, Aukrust P, Schurgers LJ (2011)
    Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure
    Clin Sci (Lond), 121 (3), 119-27
    DOI 10.1042/CS20100589, PubMed 21294711
  10. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L (2011)
    Osteoprotegerin predicts progression of chronic heart failure: results from CORONA
    Circ Heart Fail, 4 (2), 145-52
    DOI 10.1161/CIRCHEARTFAILURE.110.957332, PubMed 21216833
  11. Waehre A, Halvorsen B, Yndestad A, Husberg C, Sjaastad I, Nygård S, Dahl CP, Ahmed MS, Finsen AV, Reims H, Louch WE, Hilfiker-Kleiner D, Vinge LE, Roald B, Attramadal H, Lipp M, Gullestad L, Aukrust P, Christensen G (2011)
    Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload
    PLoS One, 6 (4), e18668
    DOI 10.1371/journal.pone.0018668, PubMed 21533157
  12. Øie E, Ueland T, Dahl CP, Bohov P, Berge C, Yndestad A, Gullestad L, Aukrust P, Berge RK (2011)
    Fatty acid composition in chronic heart failure: low circulating levels of eicosatetraenoic acid and high levels of vaccenic acid are associated with disease severity and mortality
    J Intern Med, 270 (3), 263-72
    DOI 10.1111/j.1365-2796.2011.02384.x, PubMed 21466599
  13. Aarones M, Gullestad L, Aakhus S, Ueland T, Skaardal R, Aass H, Wergeland R, Smith HJ, Aukrust P, Kongsgaard E (2011)
    Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy
    Am Heart J, 161 (6), 1031-7
    DOI 10.1016/j.ahj.2010.09.021, PubMed 21641347

Publications 2010

  1. Arora S, Gunther A, Wennerblom B, Ueland T, Andreassen AK, Gude E, Endresen K, Geiran O, Wilhelmsen N, Andersen R, Aukrust P, Gullestad L (2010)
    Systemic markers of inflammation are associated with cardiac allograft vasculopathy and an increased intimal inflammatory component
    Am J Transplant, 10 (6), 1428-36
    DOI 10.1111/j.1600-6143.2010.03118.x, PubMed 20486911
  2. Aukrust P, Halvorsen B, Ueland T, Michelsen AE, Skjelland M, Gullestad L, Yndestad A, Otterdal K (2010)
    Activated platelets and atherosclerosis
    Expert Rev Cardiovasc Ther, 8 (9), 1297-307
    DOI 10.1586/erc.10.92, PubMed 20828352
  3. Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, Halvorsen B, Ueland T (2010)
    Tumor necrosis factor superfamily molecules in acute coronary syndromes
    Ann Med, 43 (2), 90-103
    DOI 10.3109/07853890.2010.523711, PubMed 21039303
  4. Grundtvig M, Gullestad L, Hole T, Flønæs B, Westheim A (2010)
    Characteristics, implementation of evidence-based management and outcome in patients with chronic heart failure: results from the Norwegian heart failure registry
    Eur J Cardiovasc Nurs, 10 (1), 44-9
    DOI 10.1016/j.ejcnurse.2010.04.001, PubMed 20452825
  5. Grundtvig M, Westheim A, Hole T, Flønaes B, Gullestad L, Norwegian Heart Failure Registry (2010)
    Warning on diuretic use
    J Am Coll Cardiol, 55 (23), 2609-10; author reply 2610
    DOI 10.1016/j.jacc.2010.02.039, PubMed 20513605
  6. Gude E, Andreassen AK, Arora S, Gullestad L, Grov I, Hartmann A, Leivestad T, Fiane AE, Geiran OR, Vardal M, Simonsen S (2010)
    Acute renal failure early after heart transplantation: risk factors and clinical consequences
    Clin Transplant, 24 (6), E207-13
    DOI 10.1111/j.1399-0012.2010.01225.x, PubMed 20184627
  7. Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK (2010)
    Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation
    J Heart Lung Transplant, 29 (6), 641-7
    DOI 10.1016/j.healun.2010.01.005, PubMed 20304681
  8. Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH (2010)
    Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial
    Transplantation, 89 (7), 864-72
    DOI 10.1097/TP.0b013e3181cbac2d, PubMed 20061999
  9. Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M (2010)
    Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial
    Transplantation, 90 (12), 1581-9
    DOI 10.1097/TP.0b013e3181fd01b7, PubMed 21030905
  10. Hallén J, Johansen OE, Birkeland KI, Gullestad L, Aakhus S, Endresen K, Tjora S, Jaffe AS, Atar D (2010)
    Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus
    Cardiovasc Diabetol, 9, 52
    DOI 10.1186/1475-2840-9-52, PubMed 20843304
  11. Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJ, Biessen EA (2010)
    The peripheral blood mononuclear cell microRNA signature of coronary artery disease
    Biochem Biophys Res Commun, 394 (3), 792-7
    DOI 10.1016/j.bbrc.2010.03.075, PubMed 20230787
  12. Hole T, Grundtvig M, Gullestad L, Flønæs B, Westheim A (2010)
    Improved quality of life in Norwegian heart failure patients after follow-up in outpatient heart failure clinics: results from the Norwegian Heart Failure Registry
    Eur J Heart Fail, 12 (11), 1247-52
    DOI 10.1093/eurjhf/hfq156, PubMed 20847014
  13. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L, Heart Failure Association of ESC (HFA) (2010)
    EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)
    Eur J Heart Fail, 12 (10), 1076-84
    DOI 10.1093/eurjhf/hfq154, PubMed 20805094
  14. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ (2010)
    Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis
    J Intern Med, 268 (5), 483-92
    DOI 10.1111/j.1365-2796.2010.02264.x, PubMed 20804515
  15. Waldum B, Westheim AS, Sandvik L, Flønaes B, Grundtvig M, Gullestad L, Hole T, Os I (2010)
    Renal function in outpatients with chronic heart failure
    J Card Fail, 16 (5), 374-80
    DOI 10.1016/j.cardfail.2010.01.001, PubMed 20447572
  16. Øie E, Ahmed MS, Ueland T, Sikkeland LI, Dahl CP, Hagelin EM, von Lueder T, Edvardsen T, Andreassen AK, Gullestad L, Aukrust P, Yndestad A, Vinge LE, Attramadal H (2010)
    Adrenomedullin is increased in alveolar macrophages and released from the lungs into the circulation in severe heart failure
    Basic Res Cardiol, 105 (1), 89-98
    DOI 10.1007/s00395-009-0070-y, PubMed 19823891
  17. Aarønæs M, Aakhus S, Aass H, Moum T, Wergeland R, Gullestad L, Kongsgård E (2010)
    Assessment of response criteria to cardiac resynchronization therapy (CRT) and prediction of response
    Scand Cardiovasc J, 44 (6), 337-45
    DOI 10.3109/14017431.2010.508537, PubMed 21080864

Publications 2009

  1. Arora S, Aukrust P, Andreassen A, Simonsen S, Gude E, Grov I, Geiran O, Fiane A, Gullestad L (2009)
    The prognostic importance of modifiable risk factors after heart transplantation
    Am Heart J, 158 (3), 431-6
    DOI 10.1016/j.ahj.2009.05.036, PubMed 19699867
  2. Arora S, Aukrust P, Ueland T, Broch K, Simonsen S, Gude E, Fiane AE, Geiran O, Wergeland R, Andreassen AK, Gullestad L (2009)
    Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality
    Eur J Heart Fail, 11 (10), 1005-13
    DOI 10.1093/eurjhf/hfp115, PubMed 19737803
  3. Aukrust P, Ueland T, Gullestad L, Yndestad A (2009)
    Testosterone: a novel therapeutic approach in chronic heart failure?
    J Am Coll Cardiol, 54 (10), 928-9
    DOI 10.1016/j.jacc.2009.05.039, PubMed 19712803
  4. Broch K, Gude E, Scott H, Aakhus S (2009)
    [A patient with aortic stenosis and reduced left ventricular function]
    Tidsskr Nor Laegeforen, 129 (20), 2119-21
    DOI 10.4045/tidsskr.08.0622, PubMed 19855451
  5. Dahl CP, Husberg C, Gullestad L, Waehre A, Damås JK, Vinge LE, Finsen AV, Ueland T, Florholmen G, Aakhus S, Halvorsen B, Aukrust P, Oie E, Yndestad A, Christensen G (2009)
    Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling
    Circ Heart Fail, 2 (6), 624-32
    DOI 10.1161/CIRCHEARTFAILURE.108.821074, PubMed 19919988
  6. Gjesdal O, Gude E, Arora S, Leivestad T, Andreassen AK, Gullestad L, Aaberge L, Brunvand H, Edvardsen T, Geiran OR, Simonsen S (2009)
    Intra-aortic balloon counterpulsation as a bridge to heart transplantation does not impair long-term survival
    Eur J Heart Fail, 11 (7), 709-14
    DOI 10.1093/eurjhf/hfp078, PubMed 19515719
  7. Gude E, Simonsen S, Geiran OR, Fiane AE, Gullestad L, Arora S, Relbo A, Andreassen AK (2009)
    Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics
    J Heart Lung Transplant, 29 (2), 216-23
    DOI 10.1016/j.healun.2009.08.021, PubMed 19837606
  8. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschöpe C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009)
    Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
    Eur J Heart Fail, 11 (2), 119-29
    DOI 10.1093/eurjhf/hfn043, PubMed 19168509
  9. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL (2009)
    Osteoprotegerin concentrations and prognosis in acute ischaemic stroke
    J Intern Med, 267 (4), 410-7
    DOI 10.1111/j.1365-2796.2009.02163.x, PubMed 19895657
  10. Johansen OE, Birkeland KI, Jørgensen AP, Orvik E, Sørgård B, Torjussen BR, Ueland T, Aukrust P, Gullestad L (2009)
    Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial
    J Diabetes, 1 (3), 182-7
    DOI 10.1111/j.1753-0407.2009.00031.x, PubMed 20923537
  11. Kjekshus JK, Torp-Pedersen C, Gullestad L, Køber L, Edvardsen T, Olsen IC, Sjaastad I, Qvigstad E, Skomedal T, Osnes JB, Levy FO (2009)
    Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure
    Eur J Heart Fail, 11 (8), 771-8
    DOI 10.1093/eurjhf/hfp087, PubMed 19567409
  12. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009)
    Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
    Circulation, 120 (22), 2188-96
    DOI 10.1161/CIRCULATIONAHA.109.849117, PubMed 19917888
  13. Sandberg WJ, Otterdal K, Gullestad L, Halvorsen B, Ragnarsson A, Frøland SS, Damås JK, Oie E, Aukrust P, Hansson GK, Yndestad A (2009)
    The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis
    Thromb Haemost, 102 (4), 704-10
    DOI 10.1160/TH08-10-0665, PubMed 19806256
  14. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009)
    Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003
    Arterioscler Thromb Vasc Biol, 29 (6), 975-80
    DOI 10.1161/ATVBAHA.109.184101, PubMed 19325145
  15. Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WJ, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, Oie E, Hansson GK, Aukrust P (2009)
    Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis
    Arterioscler Thromb Vasc Biol, 29 (8), 1228-34
    DOI 10.1161/ATVBAHA.109.189761, PubMed 19498175
  16. Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Øie E, Gullestad L, Aukrust P (2009)
    Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure
    Eur Heart J, 30 (10), 1229-36
    DOI 10.1093/eurheartj/ehp088, PubMed 19329498

Publications 2008

  1. Arora S, Jenum PA, Aukrust P, Rollag H, Andreassen AK, Simonsen S, Guide E, Fiane AE, Geiran O, Gullestad L (2008)
    Pre-transplant Toxoplasma gondii seropositivlty among heart transplant recipients and mortality - Reply
    J. Am. Coll. Cardiol., 51 (18), 1827-1828
    DOI 10.1016/j.jacc.2008.02.028
  2. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, Gullestad L, Damås JK (2008)
    Chemokines and cardiovascular risk
    Arterioscler Thromb Vasc Biol, 28 (11), 1909-19
    DOI 10.1161/ATVBAHA.107.161240, PubMed 18669888
  3. Aukrust P, Otterdal K, Yndestad A, Sandberg WJ, Smith C, Ueland T, Øie E, Damås JK, Gullestad L, Halvorsen B (2008)
    The complex role of T-cell-based immunity in atherosclerosis
    Curr Atheroscler Rep, 10 (3), 236-43
    DOI 10.1007/s11883-008-0037-8, PubMed 18489852
  4. Breland UM, Halvorsen B, Hol J, Øie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Frøland SS, Haraldsen G, Gullestad L, Damås JK, Hansson GK, Aukrust P (2008)
    A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins
    Arterioscler Thromb Vasc Biol, 28 (5), 1005-11
    DOI 10.1161/ATVBAHA.108.162305, PubMed 18276907
  5. Dahl CP, Gullestad L, Fevang B, Holm AM, Landrø L, Vinge LE, Fiane AE, Sandberg WJ, Otterdal K, Frøland SS, Damås JK, Halvorsen B, Aukrust P, Øie E, Yndestad A (2008)
    Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure
    Eur J Heart Fail, 10 (4), 352-9
    DOI 10.1016/j.ejheart.2008.02.010, PubMed 18353719
  6. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Øie E, Aukrust P (2008)
    Atherosclerotic plaque stability--what determines the fate of a plaque?
    Prog Cardiovasc Dis, 51 (3), 183-94
    DOI 10.1016/j.pcad.2008.09.001, PubMed 19026853
  7. Husberg C, Nygård S, Finsen AV, Damås JK, Frigessi A, Oie E, Waehre A, Gullestad L, Aukrust P, Yndestad A, Christensen G (2008)
    Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure
    J Mol Cell Cardiol, 45 (2), 261-9
    DOI 10.1016/j.yjmcc.2008.05.009, PubMed 18585734
  8. Sandberg WJ, Halvorsen B, Yndestad A, Smith C, Otterdal K, Brosstad FR, Frøland SS, Olofsson PS, Damås JK, Gullestad L, Hansson GK, Oie E, Aukrust P (2008)
    Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis
    Circ Res, 104 (1), 60-8
    DOI 10.1161/CIRCRESAHA.108.188078, PubMed 19023130
  9. Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Frøland SS, Oie E, Gullestad L, Damås JK, Aukrust P (2008)
    High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins
    Cardiovasc Res, 79 (1), 195-203
    DOI 10.1093/cvr/cvn071, PubMed 18339644

Publications 2007

  1. Arora S, Andreassen A, Simonsen S, Gude E, Dahl C, Skaardal R, Hoel I, Geiran O, Gullestad L (2007)
    Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy
    Transplantation, 84 (2), 149-54
    DOI 10.1097/01.tp.0000268810.61393.2c, PubMed 17667805
  2. Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A, Ueland T, Geiran O, Andreassen A (2007)
    Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation
    Transplantation, 83 (10), 1308-15
    DOI 10.1097/01.tp.0000263338.39555.21, PubMed 17519779
  3. Arora S, Jenum PA, Aukrust P, Rollag H, Andreassen AK, Simonsen S, Gude E, Fiane AE, Geiran O, Gullestad L (2007)
    Pre-transplant Toxoplasma gondii seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality
    J Am Coll Cardiol, 50 (20), 1967-72
    DOI 10.1016/j.jacc.2007.07.068, PubMed 17996562
  4. Aukrust P, Yndestad A, Damås JK, Ueland T, Øie E, Gullestad L (2007)
    Potential mechanisms of benefit with thalidomide in chronic heart failure
    Am J Cardiovasc Drugs, 7 (2), 127-34
    DOI 10.2165/00129784-200707020-00004, PubMed 17503883
  5. Aukrust P, Yndestad A, Sandberg WJ, Gullestad L, Damås JK (2007)
    T cells in coronary artery disease: different effects of different T-cell subsets
    J Am Coll Cardiol, 50 (15), 1459-61
    DOI 10.1016/j.jacc.2007.06.041, PubMed 17919565
  6. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damås JK (2007)
    Chemokines in cardiovascular risk prediction
    Thromb Haemost, 97 (5), 748-54
    DOI 10.1160/TH07-01-0029, PubMed 17479185
  7. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B (2007)
    Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization
    Circulation, 115 (8), 972-80
    DOI 10.1161/CIRCULATIONAHA.106.665893, PubMed 17283255
  8. Gullestad L, Madsen S (2007)
    [Diuretics not the first-choice-drug in chronic heart failure]
    Tidsskr Nor Laegeforen, 127 (5), 621; author reply 621
    PubMed 17332822
  9. Gullestad L, Oie E, Ueland T, Yndestad A, Aukrust P (2007)
    The role of statins in heart failure
    Fundam Clin Pharmacol, 21 Suppl 2, 35-40
    DOI 10.1111/j.1472-8206.2007.00538.x, PubMed 18001320
  10. Havik OE, Sivertsen B, Relbo A, Hellesvik M, Grov I, Geiran O, Andreassen AK, Simonsen S, Gullestad L (2007)
    Depressive symptoms and all-cause mortality after heart transplantation
    Transplantation, 84 (1), 97-103
    DOI 10.1097/01.tp.0000268816.90672.a0, PubMed 17627244
  11. Johansen OE, Birkeland KI, Orvik E, Flesland Ø, Wergeland R, Ueland T, Smith C, Endresen K, Aukrust P, Gullestad L (2007)
    Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects
    Scand J Clin Lab Invest, 67 (3), 306-16
    DOI 10.1080/00365510601045088, PubMed 17454845
  12. Johansen OE, Bjurö T, Endresen K, Blaasaas KG, Birkeland K, Aakhus S, Gullestad L (2007)
    Heart rate adjustments and analysis of recovery patterns of ST-segment depression in type 2 diabetes
    Int J Cardiol, 127 (1), 129-32
    DOI 10.1016/j.ijcard.2007.04.022, PubMed 17532067
  13. Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI (2007)
    Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial
    Diabet Med, 24 (9), 1019-27
    DOI 10.1111/j.1464-5491.2007.02198.x, PubMed 17509068
  14. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ et al. (2007)
    Rosuvastatin in older patients with systolic heart failure
    N Engl J Med, 357 (22), 2248-61
    DOI 10.1056/NEJMoa0706201, PubMed 17984166
  15. Otterdal K, Andreassen AK, Yndestad A, Oie E, Sandberg WJ, Dahl CP, Pedersen TM, Ueland T, Gullestad L, Brosstad FR, Aukrust P, Damås JK (2007)
    Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation
    Am J Respir Crit Care Med, 177 (2), 202-7
    DOI 10.1164/rccm.200703-506OC, PubMed 17962639
  16. Simonsen S, Andreassen AK, Gullestad L, Leivestad T, Fiane AE, Geiran OR (2007)
    [Survival after heart transplantation in Norway]
    Tidsskr Nor Laegeforen, 127 (7), 865-8
    PubMed 17435806
  17. Sivertsen B, Relbo A, Gullestad L, Hellesvik M, Grov I, Andreassen A, Simonsen S, Geiran O, Havik OE (2007)
    [Self-assessed health and psychological symptoms after heart transplantation]
    Tidsskr Nor Laegeforen, 127 (24), 3198-201
    PubMed 18084359
  18. Yndestad A, Damås JK, Øie E, Ueland T, Gullestad L, Aukrust P (2007)
    Role of inflammation in the progression of heart failure
    Curr Cardiol Rep, 9 (3), 236-41
    DOI 10.1007/BF02938356, PubMed 17470337

Publications 2006

  1. Aukrust P, Yndestad A, Ueland T, Damås JK, Frøland SS, Gullestad L (2006)
    The role of intravenous immunoglobulin in the treatment of chronic heart failure
    Int J Cardiol, 112 (1), 40-5
    DOI 10.1016/j.ijcard.2006.05.015, PubMed 16893578
  2. Aukrust P, Yndestad A, Ueland T, Damås JK, Gullestad L (2006)
    Anti-inflammatory trials in chronic heart failure
    Heart Fail Monit, 5 (1), 2-9
    PubMed 16547529
  3. Damås JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Taskén K, Frøland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P (2006)
    Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization
    Arterioscler Thromb Vasc Biol, 27 (3), 614-20
    DOI 10.1161/01.ATV.0000255581.38523.7c, PubMed 17170367
  4. Holm T, Ueland T, Halvorsen B, Hognestad A, Holm AG, Wergeland R, Gullestad L, Aukrust P, Kjekshus J (2006)
    A protective anti-inflammatory phenotype in high-risk individuals who do not develop coronary artery disease
    J Am Coll Cardiol, 47 (5), 1085-6
    DOI 10.1016/j.jacc.2005.11.042, PubMed 16516099
  5. Johansen OE, Birkeland KI, Brustad E, Aaser E, Lindahl AK, Midha R, Ueland T, Aukrust P, Gullestad L (2006)
    Undiagnosed dysglycaemia and inflammation in cardiovascular disease
    Eur J Clin Invest, 36 (8), 544-51
    DOI 10.1111/j.1365-2362.2006.01679.x, PubMed 16893376
  6. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P (2006)
    Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization
    Arterioscler Thromb Vasc Biol, 26 (4), 857-63
    DOI 10.1161/01.ATV.0000204334.48195.6a, PubMed 16424351
  7. Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P (2006)
    Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation
    J Am Coll Cardiol, 48 (8), 1591-9
    DOI 10.1016/j.jacc.2006.06.060, PubMed 17045893
  8. Ueland T, Aukrust P, Damas JK, Gullestad L, Yndestad A (2006)
    The tumor necrosis factor superfamily in heart failure
    Future Cardiol, 2 (1), 101-11
    DOI 10.2217/14796678.2.1.101, PubMed 19804137
  9. Ueland T, Espevik T, Kjekshus J, Gullestad L, Omland T, Squire IB, Frøland SS, Mollnes TE, Dickstein K, Aukrust P (2006)
    Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction
    J Card Fail, 12 (8), 659-63
    DOI 10.1016/j.cardfail.2006.07.002, PubMed 17045187
  10. Ueland T, Gullestad L, Simonsen S, Endresen K, Scott H, Frøland SS, Geiran O, Fiane AE, Aukrust P (2006)
    Decreased endomyocardial RANKL expression in transplant coronary artery disease
    Transplantation, 81 (10), 1467-70
    DOI 10.1097/01.tp.0000209413.45179.f6, PubMed 16732187
  11. Ueland T, Vissers MN, Wiegman A, Rodenburg J, Hutten B, Gullestad L, Ose L, Rifai N, Ridker PM, Kastelein JJ, Aukrust P, Semb AG (2006)
    Increased inflammatory markers in children with familial hypercholesterolaemia
    Eur J Clin Invest, 36 (3), 147-52
    DOI 10.1111/j.1365-2362.2006.01613.x, PubMed 16506958
  12. van Veldhuisen DJ, Aass H, El Allaf D, Dunselman PH, Gullestad L, Halinen M, Kjekshus J, Ohlsson L, Wedel H, Wikstrand J, MERIT-HF Study Group (2006)
    Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study
    Eur J Heart Fail, 8 (5), 539-46
    DOI 10.1016/j.ejheart.2006.01.015, PubMed 16567126
  13. Waehre T, Damås JK, Pedersen TM, Gullestad L, Yndestad A, Andreassen AK, Frøland SS, Semb AG, Hansteen V, Gjertsen E, Ueland T, Brosstad F, Solum NO, Aukrust P (2006)
    Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study
    J Thromb Haemost, 4 (10), 2140-7
    DOI 10.1111/j.1538-7836.2006.02131.x, PubMed 16856976
  14. Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P (2006)
    Systemic inflammation in heart failure--the whys and wherefores
    Heart Fail Rev, 11 (1), 83-92
    DOI 10.1007/s10741-006-9196-2, PubMed 16819581

Publications 2005

  1. Aukrust P, Gullestad L, Ueland T, Damås JK, Yndestad A (2005)
    Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications
    Ann Med, 37 (2), 74-85
    DOI 10.1080/07853890510007232, PubMed 16026115
  2. Aukrust P, Yndestad A, Smith C, Sandberg WJ, Ueland T, Waehre T, Halvorsen B, Gullestad L, Damås JK (2005)
    Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation
    Expert Opin Pharmacother, 6 (13), 2169-80
    DOI 10.1517/14656566.6.13.2169, PubMed 16218879
  3. Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damås JK (2005)
    Inflammation in coronary artery disease: potential role for immunomodulatory therapy
    Expert Rev Cardiovasc Ther, 3 (6), 1111-24
    DOI 10.1586/14779072.3.6.1111, PubMed 16293001
  4. Fiane AE, Ueland T, Simonsen S, Scott H, Endresen K, Gullestad L, Geiran OR, Haraldsen G, Heggelund L, Andreassen AK, Wergeland R, Frøland S, Aukrust P, Mollnes TE (2005)
    Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation
    Eur Heart J, 26 (16), 1660-5
    DOI 10.1093/eurheartj/ehi198, PubMed 15821010
  5. Gullestad L, Aukrust P (2005)
    Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches
    Am J Cardiol, 95 (11A), 17C-23C; discussion 38C-40C
    DOI 10.1016/j.amjcard.2005.03.008, PubMed 15925560
  6. Gullestad L, Kjekshus J, Damås JK, Ueland T, Yndestad A, Aukrust P (2005)
    Agents targeting inflammation in heart failure
    Expert Opin Investig Drugs, 14 (5), 557-66
    DOI 10.1517/13543784.14.5.557, PubMed 15926863
  7. Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, Følling M, Hodt A, Skårdal R, Kjekshus J, Andreassen A, Kjekshus E, Wergeland R, Yndestad A, Frøland SS, Semb AG, Aukrust P (2005)
    Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study
    Circulation, 112 (22), 3408-14
    DOI 10.1161/CIRCULATIONAHA.105.564971, PubMed 16301340
  8. Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U, Gottlieb S, Rashkow A, Wedel H, Bermann G, Kjekshus J, MERIT-HF Study Group (2005)
    What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
    J Am Coll Cardiol, 45 (2), 252-9
    DOI 10.1016/j.jacc.2004.10.032, PubMed 15653024
  9. Scholz H, Sandberg W, Damås JK, Smith C, Andreassen AK, Gullestad L, Frøland SS, Yndestad A, Aukrust P, Halvorsen B (2005)
    Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis
    Circulation, 112 (14), 2121-9
    DOI 10.1161/CIRCULATIONAHA.105.544676, PubMed 16186421
  10. Ueland T, Aukrust P, Yndestad A, Otterdal K, Frøland SS, Dickstein K, Kjekshus J, Gullestad L, Damås JK (2005)
    Soluble CD40 ligand in acute and chronic heart failure
    Eur Heart J, 26 (11), 1101-7
    DOI 10.1093/eurheartj/ehi132, PubMed 15716285
  11. Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, Gullestad L, Dickstein K, Aukrust P (2005)
    Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients
    J Am Coll Cardiol, 46 (11), 2018-21
    DOI 10.1016/j.jacc.2005.08.039, PubMed 16325035
  12. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P (2005)
    Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure
    Circulation, 111 (19), 2461-8
    DOI 10.1161/01.CIR.0000165119.62099.14, PubMed 15883214

Publications 2004

  1. Aukrust P, Yndestad A, Damås JK, Gullestad L (2004)
    Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin
    Autoimmun Rev, 3 (3), 221-7
    DOI 10.1016/S1568-9972(03)00103-4, PubMed 15110235
  2. Aukrust P, Yndestad A, Damås JK, Gullestad L (2004)
    Therapeutic potential of anticytokine therapy in congestive heart failure
    Am J Cardiovasc Drugs, 4 (3), 169-77
    DOI 10.2165/00129784-200404030-00004, PubMed 15134469
  3. Bjurö T, Gullestad L, Endresen K, Nordlander M, Malm A, Höglund L, Wahlqvist I, Pernow J (2004)
    Evaluation of ST-segment changes during and after maximal exercise tests in one-, two- and three-vessel coronary artery disease
    Scand Cardiovasc J, 38 (5), 270-7
    DOI 10.1080/14017430410021606, PubMed 15513309
  4. Gullestad L, Madsen S (2004)
    [Modern diagnosis and treatment of heart failure]
    Tidsskr Nor Laegeforen, 124 (8), 1107-10
    PubMed 15114390
  5. Gullestad L, Myers J, Edvardsen T, Kjekshus J, Geiran O, Simonsen S (2004)
    Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipients
    Am Heart J, 147 (1), 49-54
    DOI 10.1016/j.ahj.2003.07.013, PubMed 14691418
  6. Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, Holm T, Andreassen AK, Kjekshus JK (2004)
    Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation
    Clin Cardiol, 27 (4), 199-203
    DOI 10.1002/clc.4960270405, PubMed 15119693
  7. Hole T, Frøland G, Gullestad L, Offstad J, Skjaerpe T (2004)
    Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure
    Echocardiography, 21 (3), 215-23
    DOI 10.1111/j.0742-2822.2004.03102.x, PubMed 15053783
  8. Larsson L, Mobini R, Aukrust P, Gullestad L, Wallukat G, Waagstein F, Fu M (2004)
    Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody
    Autoimmunity, 37 (6-7), 489-93
    DOI 10.1080/08916930400011684, PubMed 15621576
  9. Smith C, Yndestad A, Halvorsen B, Ueland T, Waehre T, Otterdal K, Scholz H, Endresen K, Gullestad L, Frøland SS, Damås JK, Aukrust P (2004)
    Potential anti-inflammatory role of activin A in acute coronary syndromes
    J Am Coll Cardiol, 44 (2), 369-75
    DOI 10.1016/j.jacc.2004.03.069, PubMed 15261933
  10. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L (2004)
    Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion
    Am J Cardiol, 93 (6), 780-2
    DOI 10.1016/j.amjcard.2003.12.009, PubMed 15019894
  11. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P (2004)
    Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction
    J Am Coll Cardiol, 44 (10), 1970-6
    DOI 10.1016/j.jacc.2004.06.076, PubMed 15542278
  12. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Frøland SS, Semb AG, Aukrust P, Damås JK (2004)
    Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors
    Circulation, 109 (16), 1966-72
    DOI 10.1161/01.CIR.0000125700.33637.B1, PubMed 15051633
  13. Yndestad A, Ueland T, Øie E, Florholmen G, Halvorsen B, Attramadal H, Simonsen S, Frøland SS, Gullestad L, Christensen G, Damås JK, Aukrust P (2004)
    Elevated levels of activin A in heart failure: potential role in myocardial remodeling
    Circulation, 109 (11), 1379-85
    DOI 10.1161/01.CIR.0000120704.97934.41, PubMed 14993131

Publications 2003

  1. Aukrust P, Damås JK, Gullestad L (2003)
    Immunomodulating therapy: new treatment modality in congestive heart failure
    Congest Heart Fail, 9 (2), 64-9
    DOI 10.1111/j.1527-5299.2003.00682.x, PubMed 12671336
  2. Damås JK, Waehre T, Yndestad A, Otterdal K, Hognestad A, Solum NO, Gullestad L, Frøland SS, Aukrust P (2003)
    Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets
    Circulation, 107 (21), 2670-6
    DOI 10.1161/01.CIR.0000070542.18001.87, PubMed 12742982
  3. Gullestad L, Bjurø T, Aaberge L, Apelland T, Skårdal R, Kjekshus E, Nordlander M, Ablad B, Pernow J (2003)
    The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris
    Eur Heart J, 24 (12), 1120-7
    DOI 10.1016/s0195-668x(03)00209-4, PubMed 12804926
  4. Gullestad L, Kjekshus J (2003)
    [Use of beta-blockaders in heart failure]
    Tidsskr Nor Laegeforen, 123 (5), 651-2
    PubMed 12683197
  5. Holm T, Damås JK, Holven K, Nordøy I, Brosstad FR, Ueland T, Währe T, Kjekshus J, Frøland SS, Eiken HG, Solum NO, Gullestad L, Nenseter M, Aukrust P (2003)
    CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells
    J Thromb Haemost, 1 (2), 257-62
    DOI 10.1046/j.1538-7836.2003.00065.x, PubMed 12871498
  6. Myers J, Geiran O, Simonsen S, Ghuyoumi A, Gullestad L (2003)
    Clinical and exercise test determinants of survival after cardiac transplantation
    Chest, 124 (5), 2000-5
    DOI 10.1378/chest.124.5.2000, PubMed 14605079
  7. Myers J, Gullestad L, Bellin D, Ross H, Vagelos R, Fowler M (2003)
    Physical activity patterns and exercise performance in cardiac transplant recipients
    J Cardiopulm Rehabil, 23 (2), 100-6
    DOI 10.1097/00008483-200303000-00006, PubMed 12668931
  8. Ronnevig M, Bjorsvik E, Gullestad L, Forfang K (2003)
    A descriptive study of early nonspecific chest pain after PTCA: important area for the acute health care personnel
    Heart Lung, 32 (4), 241-9
    DOI 10.1016/s0147-9563(03)00024-4, PubMed 12891164
  9. Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF (2003)
    Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
    J Am Coll Cardiol, 41 (2), 275-9
    DOI 10.1016/s0735-1097(02)02718-3, PubMed 12535822
  10. Ueland T, Sikkeland LI, Yndestad A, Eiken HG, Holm T, Guevara C, Haug T, Endresen K, Frøland SS, Gullestad L, Andreassen AK, Geiran O, Simonsen S, Aukrust P (2003)
    Myocardial gene expression of inflammatory cytokines after heart transplantation in relation to the development of transplant coronary artery disease
    Am J Cardiol, 92 (6), 715-7
    DOI 10.1016/s0002-9149(03)00836-1, PubMed 12972116
  11. Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Frøland SS, Semb AG, Aukrust P (2003)
    Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease
    J Am Coll Cardiol, 41 (9), 1460-7
    DOI 10.1016/s0735-1097(03)00263-8, PubMed 12742282
  12. Yndestad A, Holm AM, Müller F, Simonsen S, Frøland SS, Gullestad L, Aukrust P (2003)
    Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure
    Cardiovasc Res, 60 (1), 141-6
    DOI 10.1016/s0008-6363(03)00362-6, PubMed 14522416

Publications 2002

  1. Damås JK, Waehre T, Yndestad A, Ueland T, Müller F, Eiken HG, Holm AM, Halvorsen B, Frøland SS, Gullestad L, Aukrust P (2002)
    Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects
    Circulation, 106 (1), 36-42
    DOI 10.1161/01.cir.0000020001.09990.90, PubMed 12093767
  2. Gottlieb SS, Fisher ML, Kjekshus J, Deedwania P, Gullestad L, Vitovec J, Wikstrand J, MERIT-HF Investigators (2002)
    Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
    Circulation, 105 (10), 1182-8
    DOI 10.1161/hc1002.105180, PubMed 11889011
  3. Gullestad L, Semb AG, Holt E, Skårdal R, Ueland T, Yndestad A, Frøland SS, Aukrust P (2002)
    Effect of thalidomide in patients with chronic heart failure
    Am Heart J, 144 (5), 847-50
    DOI 10.1067/mhj.2002.125628, PubMed 12422154
  4. Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad TS, Kjekshus J, Simonsen S, Frøland SS, Gullestad L, Andreassen AK (2002)
    Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension
    Transplantation, 74 (10), 1395-400
    DOI 10.1097/00007890-200211270-00009, PubMed 12451238
  5. Lund TM, Torsvik H, Falch D, Christophersen B, Skårdal R, Gullestad L (2002)
    Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease
    Am J Cardiol, 90 (7), 784-6
    DOI 10.1016/s0002-9149(02)02614-0, PubMed 12356401
  6. Waehre T, Halvorsen B, Damås JK, Yndestad A, Brosstad F, Gullestad L, Kjekshus J, Frøland SS, Aukrust P (2002)
    Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10
    Eur J Clin Invest, 32 (11), 803-10
    DOI 10.1046/j.1365-2362.2002.01069.x, PubMed 12423320
  7. Yndestad A, Damås JK, Geir Eiken H, Holm T, Haug T, Simonsen S, Frøland SS, Gullestad L, Aukrust P (2002)
    Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure
    Cardiovasc Res, 54 (1), 175-82
    DOI 10.1016/s0008-6363(02)00238-9, PubMed 12062373

Publications 2001

  1. Aukrust P, Berge RK, Ueland T, Aaser E, Damås JK, Wikeby L, Brunsvig A, Müller F, Forfang K, Frøland SS, Gullestad L (2001)
    Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes
    J Am Coll Cardiol, 37 (2), 485-91
    DOI 10.1016/s0735-1097(00)01110-4, PubMed 11216967
  2. Aukrust P, Damås JK, Gullestad L, Frøland SS (2001)
    Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets
    Clin Exp Immunol, 124 (3), 343-5
    DOI 10.1046/j.1365-2249.2001.01527.x, PubMed 11472392
  3. Aukrust P, Gullestad L, Lappegård KT, Ueland T, Aass H, Wikeby L, Simonsen S, Frøland SS, Mollnes TE (2001)
    Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment
    Circulation, 104 (13), 1494-500
    DOI 10.1161/hc3801.096353, PubMed 11571242
  4. Aukrust P, Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Froland SS (2001)
    Increase in anti-inflammatory cytokine levels in chronic heart failure: A measure of treatment success or failure? Response
    Circulation, 104 (18), E97-E98
  5. Aukrust P, Waehre T, Damås JK, Gullestad L, Solum NO (2001)
    Inflammatory role of platelets in acute coronary syndromes
    Heart, 86 (6), 605-6
    DOI 10.1136/heart.86.6.605, PubMed 11711447
  6. Dahle MG, Gullestad L, Simonsen S (2001)
    Plasma N-terminal proatrial natriuretic factor can predict normal pulmonary capillary wedge pressure in cardiac transplant recipients
    Scand Cardiovasc J, 35 (6), 367-71
    DOI 10.1080/14017430152754844, PubMed 11837515
  7. Damås JK, Aukrust P, Ueland T, Odegaard A, Eiken HG, Gullestad L, Sejersted OM, Christensen G (2001)
    Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes
    Basic Res Cardiol, 96 (4), 345-52
    DOI 10.1007/s003950170042, PubMed 11518190
  8. Damås JK, Gullestad L, Aukrust P (2001)
    Cytokines as new treatment targets in chronic heart failure
    Curr Control Trials Cardiovasc Med, 2 (6), 271-277
    DOI 10.1186/cvm-2-6-271, PubMed 11806813
  9. Damås JK, Gullestad L, Aass H, Simonsen S, Fjeld JG, Wikeby L, Ueland T, Eiken HG, Frøland SS, Aukrust P (2001)
    Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin
    J Am Coll Cardiol, 38 (1), 187-93
    DOI 10.1016/s0735-1097(01)01335-3, PubMed 11451272
  10. Eiken HG, Øie E, Damås JK, Yndestad A, Bjerkeli V, Aass H, Simonsen S, Geiran OR, Tønnessen T, Christensen G, Frøland SS, Gullestad L, Attramadal H, Aukrust P (2001)
    Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure
    Eur J Clin Invest, 31 (5), 389-97
    DOI 10.1046/j.1365-2362.2001.00795.x, PubMed 11380590
  11. Gullestad L, Aukrust P (2001)
    The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets
    Heart Fail Monit, 2 (1), 8-13
    PubMed 12634893
  12. Gullestad L, Manhenke C, Aarsland T, Skårdal R, Fagertun H, Wikstrand J, Kjekshus J (2001)
    Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial
    Eur J Heart Fail, 3 (4), 463-8
    DOI 10.1016/s1388-9842(01)00146-5, PubMed 11511433
  13. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Frøland SS, Aukrust P (2001)
    Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF)
    Am Heart J, 141 (3), 418-21
    DOI 10.1067/mhj.2001.112785, PubMed 11231439
  14. Gullestad L, Aass H, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Wikeby L, Nitter-Hauge S, Fjeld JG, Lien E, Ueland T, Frøland SS, Aukrust P (2001)
    [Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]
    Tidsskr Nor Laegeforen, 121 (16), 1902-7
    PubMed 11488180
  15. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland SS, Aukrust P (2001)
    Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure
    Circulation, 103 (2), 220-5
    DOI 10.1161/01.cir.103.2.220, PubMed 11208680
  16. Holm T, Andreassen AK, Aukrust P, Andersen K, Geiran OR, Kjekshus J, Simonsen S, Gullestad L (2001)
    Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients
    Eur Heart J, 22 (5), 428-36
    DOI 10.1053/euhj.2000.2369, PubMed 11207085
  17. Holm T, Andreassen AK, Ueland T, Kjekshus J, Frøland SS, Kjekshus E, Simonsen S, Aukrust P, Gullestad L (2001)
    Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients
    Am J Cardiol, 87 (6), 815-8, A9
    DOI 10.1016/s0002-9149(00)01516-2, PubMed 11249916
  18. Holm T, Berge RK, Andreassen AK, Ueland T, Kjekshus J, Simonsen S, Frøland S, Gullestad L, Aukrust P (2001)
    Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients
    Transplantation, 72 (4), 706-11
    DOI 10.1097/00007890-200108270-00025, PubMed 11544435
  19. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenseter MS (2001)
    Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects
    Am J Med, 110 (7), 536-42
    DOI 10.1016/s0002-9343(01)00696-9, PubMed 11343667

Publications 2000

  1. Damås JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, Ueland T, Tonnessen T, Geiran OR, Aass H, Simonsen S, Christensen G, Froland SS, Attramadal H, Gullestad L, Aukrust P (2000)
    Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure
    Cardiovasc Res, 47 (4), 778-87
    DOI 10.1016/s0008-6363(00)00142-5, PubMed 10974226
  2. Damås JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Frøland SS, Aukrust P (2000)
    CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes
    Cardiovasc Res, 45 (2), 428-36
    DOI 10.1016/s0008-6363(99)00262-x, PubMed 10728363
  3. Gullestad L, Jorgensen B, Bjuro T, Pernow J, Lundberg JM, Dota CD, Hall C, Simonsen S, Ablad B (2000)
    Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease
    Circulation, 102 (9), 987-93
    DOI 10.1161/01.cir.102.9.987, PubMed 10961962
  4. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P (2000)
    Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group
    JAMA, 283 (10), 1295-302
    DOI 10.1001/jama.283.10.1295, PubMed 10714728
  5. Holm T, Aukrust P, Andreassen AK, Ueland T, Brosstad F, Frøland SS, Simonsen S, Gullestad L (2000)
    Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines
    Clin Transplant, 14 (3), 218-25
    DOI 10.1034/j.1399-0012.2000.140307.x, PubMed 10831080
  6. Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB (2000)
    Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited
    Am Heart J, 139 (1 Pt 1), 78-84
    DOI 10.1016/s0002-8703(00)90312-0, PubMed 10618566

Publications 1999

  1. Aukrust P, Gullestad L, Frøland SS (1999)
    Is apoptosis an important pathogenic factor in cardiovascular disease?
    Eur J Clin Invest, 29 (5), 369-71
    DOI 10.1046/j.1365-2362.1999.00482.x, PubMed 10354192
  2. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L (1999)
    Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes
    Circulation, 100 (6), 614-20
    DOI 10.1161/01.cir.100.6.614, PubMed 10441098
  3. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L (1999)
    Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
    Am J Cardiol, 83 (3), 376-82
    DOI 10.1016/s0002-9149(98)00872-8, PubMed 10072227
  4. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Frøland SS, Fowler M (1999)
    Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
    J Am Coll Cardiol, 34 (7), 2061-7
    DOI 10.1016/s0735-1097(99)00495-7, PubMed 10588224
  5. Gullestad L, Bjørnerheim R, Offstad J, Endresen K, Forfang K, Kjekshus J, Hansteen V (1999)
    [Current use of beta-blockers in coronary artery disease]
    Tidsskr Nor Laegeforen, 119 (1), 24-8
    PubMed 10025200
  6. Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S (1999)
    Interaction between lovastatin and cyclosporine A after heart and kidney transplantation
    Transplant Proc, 31 (5), 2163-5
    DOI 10.1016/s0041-1345(99)00295-x, PubMed 10456002
  7. Gullestad L, Simonsen S, Ueland T, Holm T, Aass H, Andreassen AK, Madsen S, Geiran O, Frøland SS, Aukrust P (1999)
    Possible role of proinflammatory cytokines in heart allograft coronary artery disease
    Am J Cardiol, 84 (9), 999-1003
    DOI 10.1016/s0002-9149(99)00487-7, PubMed 10569653
  8. Kjekshus J, Gullestad L (1999)
    Heart rate as a therapeutic target in heart failure
    Eur. Heart J. Suppl., 1 (H), H64-H69
  9. Simonsen S, Andreassen AK, Gullestad L, Lindberg H, Seem E, Geiran OR (1999)
    [Heart transplantation in Norway]
    Tidsskr Nor Laegeforen, 119 (23), 3447-50
    PubMed 10553344

Publications 1998

  1. Andreassen AK, Gullestad L, Endresen K (1998)
    [Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals]
    Tidsskr Nor Laegeforen, 118 (17), 2630-1
    PubMed 9673511
  2. Andreassen AK, Gullestad L, Holm T, Simonsen S, Kvernebo K (1998)
    Endothelium-dependent vasodilation of the skin microcirculation in heart transplant recipients
    Clin Transplant, 12 (4), 324-32
    PubMed 9686327
  3. Andreassen AK, Kirkebøen KA, Gullestad L, Simonsen S, Kvernebo K (1998)
    Effect of heart transplantation on impaired peripheral microvascular perfusion and reactivity in congestive heart failure
    Int J Cardiol, 65 (1), 33-40
    DOI 10.1016/s0167-5273(98)00103-x, PubMed 9699928
  4. Andreassen AK, Kvernebo K, Jørgensen B, Simonsen S, Kjekshus J, Gullestad L (1998)
    Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation
    Am Heart J, 136 (2), 320-8
    DOI 10.1053/hj.1998.v136.89731, PubMed 9704697
  5. Andreassen AK, Nordøy I, Simonsen S, Ueland T, Müller F, Frøland SS, Gullestad L, Aukrust P (1998)
    Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation
    Am J Cardiol, 81 (5), 604-8
    DOI 10.1016/s0002-9149(97)00972-7, PubMed 9514458
  6. Aukrust P, Ueland T, Müller F, Andreassen AK, Nordøy I, Aas H, Kjekshus J, Simonsen S, Frøland SS, Gullestad L (1998)
    Elevated circulating levels of C-C chemokines in patients with congestive heart failure
    Circulation, 97 (12), 1136-43
    DOI 10.1161/01.cir.97.12.1136, PubMed 9537339
  7. Gullestad L, Birkeland K, Bjønerheim R, Djøseland O, Trygstad O, Simonsen S (1998)
    Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment
    Growth Horm IGF Res, 8 (5), 377-84
    DOI 10.1016/s1096-6374(98)80307-9, PubMed 10984298
  8. Gullestad L, Haywood G, Aass H, Ross H, Yee G, Ueland T, Geiran O, Kjekshus J, Simonsen S, Bishopric N, Fowler M (1998)
    Angiotensin II receptor subtype AT1 and AT2 expression after heart transplantation
    Cardiovasc Res, 38 (2), 340-7
    DOI 10.1016/s0008-6363(98)00015-7, PubMed 9709394
  9. Gullestad L, Myers J, Ross H, Rickenbacher P, Slauson S, Bellin D, Do D, Vagelos R, Fowler M (1998)
    Serial exercise testing and prognosis in selected patients considered for cardiac transplantation
    Am Heart J, 135 (2 Pt 1), 221-9
    DOI 10.1016/s0002-8703(98)70085-7, PubMed 9489968
  10. Gullestad L, Aass H, Ross H, Ueland T, Geiran O, Kjekshus J, Simonsen S, Fowler M, Kobilka B (1998)
    Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation
    J Auton Nerv Syst, 70 (1-2), 84-91
    DOI 10.1016/s0165-1838(98)00032-0, PubMed 9686908
  11. Myers J, Gullestad L (1998)
    The role of exercise testing and gas-exchange measurement in the prognostic assessment of patients with heart failure
    Curr Opin Cardiol, 13 (3), 145-55
    PubMed 9649936
  12. Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB (1998)
    Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure
    Ann Intern Med, 129 (4), 286-93
    DOI 10.7326/0003-4819-129-4-199808150-00004, PubMed 9729181
  13. Risum O, Arafa O, Svennevig JL, Levorstad K, Abdelnoor M, Gullestad L, Bjørnerheim R, Simonsen S, Nitter-Hauge S (1998)
    [Mortality and morbidity after coronary bypass surgery in high-risk patients]
    Tidsskr Nor Laegeforen, 118 (29), 4504-8
    PubMed 9889633

Publications 1997

  1. Gullestad L, Myers J, Bjornerheim R, Berg KJ, Djoseland O, Hall C, Lund K, Kjekshus J, Simonsen S (1997)
    Gas exchange and neurohumoral response to exercise: influence of the exercise protocol
    Med Sci Sports Exerc, 29 (4), 496-502
    DOI 10.1097/00005768-199704000-00011, PubMed 9107632
  2. Gullestad L, Nordal KP, Forfang K, Ihlen H, Høstmark A, Berg KJ, Cheng H, Schwartz MS, Geiran O, Simonsen S (1997)
    Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin
    J Intern Med, 242 (6), 483-90
    DOI 10.1111/j.1365-2796.1997.tb00021.x, PubMed 9437409
  3. Gullestad L, Ross H, Myers J, Hoang K, Hunt S, Stinson EB, Valantine HA (1997)
    Importance of decreased heart rate in predicting transplant coronary artery disease
    Clin Transplant, 11 (6), 628-32
    PubMed 9408698
  4. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB (1997)
    AT1 and AT2 angiotensin receptor gene expression in human heart failure
    Circulation, 95 (5), 1201-6
    DOI 10.1161/01.cir.95.5.1201, PubMed 9054850
  5. Kløw NE, Smith HJ, Gullestad L, Seem E, Endresen K (1997)
    Outcome of bypass surgery in patients with chronic ischemic left ventricular dysfunction. Predictive value of MR imaging
    Acta Radiol, 38 (1), 76-82
    DOI 10.1080/02841859709171246, PubMed 9059406
  6. Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA (1997)
    Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study
    J Heart Lung Transplant, 16 (2), 179-89
    PubMed 9059929
  7. Aaser E, Gullestad L, Tølløfsrud S, Lundberg J, Hall C, Djøseland O, Kjekshus J, Forfang K (1997)
    Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure
    Scand J Clin Lab Invest, 57 (4), 361-7
    DOI 10.3109/00365519709099409, PubMed 9249883

Publications 1996

  1. Gullestad L, Hallen J, Medbø JI, Grønnerød O, Holme I, Sejersted OM (1996)
    The effect of acute vs chronic treatment with beta-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women
    Br J Clin Pharmacol, 41 (1), 57-67
    DOI 10.1111/j.1365-2125.1996.tb00159.x, PubMed 8824694
  2. Gullestad L, Haywood G, Ross H, Bjornerheim R, Geiran O, Kjekshus J, Simonsen S, Fowler M (1996)
    Exercise capacity of heart transplant recipients: the importance of chronotropic incompetence
    J Heart Lung Transplant, 15 (11), 1075-83
    PubMed 8956116
  3. Gullestad L, Myers J, Noddeland H, Bjørnerheim R, Djøseland O, Hall C, Gieran O, Kjekshus J, Simonsen S (1996)
    Influence of the exercise protocol on hemodynamic, gas exchange, and neurohumoral responses to exercise in heart transplant recipients
    J Heart Lung Transplant, 15 (3), 304-13
    PubMed 8777215
  4. Haywood GA, Rickenbacher PR, Trindade PT, Gullestad L, Jiang JP, Schroeder JS, Vagelos R, Oyer P, Fowler MB (1996)
    Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria
    Heart, 75 (5), 455-62
    DOI 10.1136/hrt.75.5.455, PubMed 8665337
  5. Risum O, Abdelnoor M, Svennevig JL, Levorstad K, Gullestad L, Bjørnerheim R, Simonsen S, Nitter-Hauge S (1996)
    Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery
    Scand J Thorac Cardiovasc Surg, 30 (2), 71-5
    DOI 10.3109/14017439609107245, PubMed 8857678
  6. Ross HJ, Gullestad L, Hunt SA, Tovey DA, Puryear JB, McMillan A, Stinson EB, Valantine HA (1996)
    Early Doppler echocardiographic dysfunction is associated with an increased mortality after orthotopic cardiac transplantation
    Circulation, 94 (9 Suppl), II289-93
    PubMed 8901762

Publications 1995

  1. Andreassen AK, Gullestad L, Bjørnerheim R, Forfang K, Kjekshus J (1995)
    [Intermittent claudication and beta-blockaders. An unfortunate combination?]
    Tidsskr Nor Laegeforen, 115 (6), 725-8
    PubMed 7900137
  2. Forfang K, Gullestad L (1995)
    [Drug therapy of angina pectoris. Are the possibilities exploited well enough?]
    Tidsskr Nor Laegeforen, 115 (18), 2264-7
    PubMed 7652725
  3. Gullestad L, Hallén J, Sejersted OM (1995)
    K+ balance of the quadriceps muscle during dynamic exercise with and without beta-adrenoceptor blockade
    J Appl Physiol (1985), 78 (2), 513-23
    DOI 10.1152/jappl.1995.78.2.513, PubMed 7759420
  4. Gullestad L, Osnes JB (1995)
    [Beta 3-receptors: incidence and properties, possible clinical significance]
    Tidsskr Nor Laegeforen, 115 (1), 45-9
    PubMed 7846660
  5. Gullestad L, Simonsen S, Kjekshus J (1995)
    [Reduced physical tolerance in patients with heart failure. Mechanisms and therapeutic effects]
    Tidsskr Nor Laegeforen, 115 (1), 38-42
    PubMed 7846658
  6. Simonsen S, Forfang K, Gullestad L, Geiran O (1995)
    [Treatment of terminal heart failure]
    Tidsskr Nor Laegeforen, 115 (4), 467-70
    PubMed 7871502
  7. Simonsen S, Gullestad L, Forfang K, Ihlen H, Nordal KP, Geiran O, Høstmark AT (1995)
    [Hypercholesterolemia--a clinical problem in heart transplantation. A therapeutic trial with low-dose lovastatin]
    Tidsskr Nor Laegeforen, 115 (3), 357-9
    PubMed 7855835

Publications 1994

  1. Børsheim E, Bahr R, Hansson P, Gullestad L, Hallén J, Sejersted OM (1994)
    Effect of beta-adrenoceptor blockade on post-exercise oxygen consumption
    Metabolism, 43 (5), 565-71
    DOI 10.1016/0026-0495(94)90197-x, PubMed 7909912
  2. Gullestad L, Jacobsen T, Dolva LO (1994)
    Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients
    Diabetes Care, 17 (5), 460-1
    DOI 10.2337/diacare.17.5.460, PubMed 8062622
  3. Gullestad L, Midtvedt K, Dolva LO, Norseth J, Kjekshus J (1994)
    The magnesium loading test: reference values in healthy subjects
    Scand J Clin Lab Invest, 54 (1), 23-31
    DOI 10.3109/00365519409086506, PubMed 8171268
  4. Gullestad L, Nes M, Rønneberg R, Midtvedt K, Falch D, Kjekshus J (1994)
    Magnesium status in healthy free-living elderly Norwegians
    J Am Coll Nutr, 13 (1), 45-50
    DOI 10.1080/07315724.1994.10718370, PubMed 8157853
  5. Hallén J, Gullestad L, Sejersted OM (1994)
    K+ shifts of skeletal muscle during stepwise bicycle exercise with and without beta-adrenoceptor blockade
    J Physiol, 477 (Pt 1), 149-59
    DOI 10.1113/jphysiol.1994.sp020179, PubMed 8071881
  6. SEJERSTED OM, HALLEN J, GULLESTAD L (1994)
    BETA-ADRENERGIC CONTROL OF POTASSIUM SHIFTS DURING EXERCISE
    EUROPEAN SECTION MEETING - INTERNATIONAL SOCIETY FOR HEART RESEARCH, 151-158

Publications 1993

  1. Andreassen AK, Gullestad L (1993)
    [Alpha blockers--first choice or second choice antihypertensive preparations?]
    Tidsskr Nor Laegeforen, 113 (10), 1256-7
    PubMed 8098555
  2. Gullestad L, Birkeland K, Mølstad P, Høyer MM, Vanberg P, Kjekshus J (1993)
    The effect of magnesium versus verapamil on supraventricular arrhythmias
    Clin Cardiol, 16 (5), 429-34
    DOI 10.1002/clc.4960160512, PubMed 8504578
  3. Gullestad L, Hallén J, Sejersted OM (1993)
    Variable effects of beta-adrenoceptor blockade on muscle blood flow during exercise
    Acta Physiol Scand, 149 (3), 257-71
    DOI 10.1111/j.1748-1716.1993.tb09621.x, PubMed 7906074

Publications 1992

  1. Gullestad L, Dolva LO, Søyland E, Manger AT, Falch D, Kjekshus J (1992)
    Oral magnesium supplementation improves metabolic variables and muscle strength in alcoholics
    Alcohol Clin Exp Res, 16 (5), 986-90
    DOI 10.1111/j.1530-0277.1992.tb01906.x, PubMed 1443440
  2. Gullestad L, Dolva LO, Waage A, Falch D, Fagerthun H, Kjekshus J (1992)
    Magnesium deficiency diagnosed by an intravenous loading test
    Scand J Clin Lab Invest, 52 (4), 245-53
    DOI 10.3109/00365519209088355, PubMed 1439510
  3. Gullestad L, Forfang K, Simonsen S (1992)
    Differential effect of selective beta 1 and nonselective beta-adrenoceptor blockade on epinephrine and atropine response in normal humans
    J Cardiovasc Pharmacol, 20 (6), 976-81
    DOI 10.1097/00005344-199212000-00019, PubMed 1282602
  4. Gullestad L, Kjekshus J (1992)
    [Sudden cardiac death. Significance of beta blockaders]
    Tidsskr Nor Laegeforen, 112 (22), 2843-7
    PubMed 1357774
  5. Gullestad L, Kjekshus J (1992)
    [Myocardial disease in diabetes mellitus]
    Tidsskr Nor Laegeforen, 112 (8), 1016-9
    PubMed 1553723

Publications 1991

  1. Birkeland KI, Gullestad L, Torsvik H (1991)
    [Cholesterol-lowering effect of oat]
    Tidsskr Nor Laegeforen, 111 (17), 2081-5
    PubMed 1871737
  2. Gullestad L, Birkeland K, Nordby G, Larsen S, Kjekshus J (1991)
    Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men
    Br J Clin Pharmacol, 32 (2), 201-7
    DOI 10.1111/j.1365-2125.1991.tb03882.x, PubMed 1681847
  3. Gullestad L, Fløgstad T, Nordstrand K, Smith G, Smith H, Frøysaker T, Simonsen S (1991)
    Intrapericardial left atrial aneurysm diagnosed by transoesophageal echocardiography and nuclear magnetic resonance imaging
    Eur Heart J, 12 (2), 277-9
    DOI 10.1093/oxfordjournals.eurheartj.a059881, PubMed 2044565
  4. Gullestad L, Oystein Dolva L, Birkeland K, Falch D, Fagertun H, Kjekshus J (1991)
    Oral versus intravenous magnesium supplementation in patients with magnesium deficiency
    Magnes Trace Elem, 10 (1), 11-6
    PubMed 1814318

Publications 1990

  1. BIRKELAND KI, GULLESTAD L, FALCH D, TORSVIK H (1990)
    OAT BRAN AND SERUM-CHOLESTEROL
    N. Engl. J. Med., 322 (24), 1748-1749

Publications 1989

  1. Gullestad L, Dolva LO, Kjeldsen SE, Eide I, Kjekshus J (1989)
    Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise
    Cardiovasc Drugs Ther, 3 (1), 63-71
    DOI 10.1007/BF01881530, PubMed 2577280
  2. Gullestad L, Dolva LO, Nordby G, Skaaraas K, Larsen S, Kjekshus J (1989)
    The importance of potassium and lactate for maximal exercise performance during beta blockade
    Scand J Clin Lab Invest, 49 (6), 521-8
    DOI 10.3109/00365518909089131, PubMed 2574496
  3. Gullestad L, Dolva LO, Søyland E, Kjekshus J (1989)
    [Beta blockaders and physical performance. Limiting factors]
    Tidsskr Nor Laegeforen, 109 (25), 2544-7
    PubMed 2573167
  4. Gullestad L, Dolva LO, Aase O, Kjekshus J (1989)
    Interaction of naloxone and timolol on maximal exercise capacity and the subjective perception of fatigue
    Int J Sports Med, 10 (4), 259-63
    DOI 10.1055/s-2007-1024912, PubMed 2606592

Publications 1988

  1. Gullestad L, Dolva LO, Søyland E, Kjekshus J (1988)
    Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise
    Clin Physiol, 8 (5), 487-99
    DOI 10.1111/j.1475-097x.1988.tb00214.x, PubMed 3191663

Publications 1987

  1. Gullestad L, Dolva LO, Kjeldsen SE, Eide I, Kjekshus J (1987)
    The effects of naloxone and timolol on plasma catecholamine levels during short-term dynamic exercise
    Scand J Clin Lab Invest, 47 (8), 847-51
    PubMed 2893446
  2. Gullestad L, Søyland E, Dolva LO, Kjekshus J (1987)
    [Angiotensin-converting enzyme inhibitors in heart failure]
    Tidsskr Nor Laegeforen, 107 (25), 2112-6
    PubMed 2823410
  3. Gullestad L, Søyland E, Kjekshus J, Aase O, Bjørnstad P (1987)
    [Magnesium deficiency. Diagnosis and occurrence of different disease conditions]
    Tidsskr Nor Laegeforen, 107 (22), 1751-4
    PubMed 3660356

Publications 1986

  1. Gullestad L, Søyland E, Kjekshus J (1986)
    [Magnesium and cardiovascular diseases]
    Tidsskr Nor Laegeforen, 106 (7), 554-7
    PubMed 3961781

Publications 1979

  1. Gullestad L, Krüger MB, Krüger O, Bakketeig LS (1979)
    [Smoking habits among pregnant women in Trøndelag]
    Tidsskr Nor Laegeforen, 99 (12), 575-9
    PubMed 442031

 
Page visits: 8490